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Chapter 1
Introduction
The continuous use of antibiotics has resulted in multi-resistant bacterial strains all over
the world. The emergence of resistance to commonly used antibiotics has stimulated
the search for new naturally occurring bactericidal and fungicidal agents that may have
clinical utility. Antimicrobial peptides (AMPs) are widely distributed effector molecules of
innate immunity in animal kingdom that provide a first line of defense against an array of
microorganisms (Liu et al., 2000; Vizioli and Salzet, 2002). AMPs of animal originmay be an
effective alternative or additive of conventional antibiotics for therapeutic use (Hancock
and Chapple, 1999). Phase I and II trials have shown a limited resistance of AMPs for
the bacterial strains tested (Zasloff, 2002). These features make the antibiotic peptides a
powerful arsenal of molecules that could be the antimicrobial drugs of the new century.
1.1 Chemical antibiotics: an unsolved and growing problem
Antibiotics are chemical substances produced by microorganisms that either destroy or
inhibit the growth of other microorganisms. Antibiotics can have a broad spectrum of
activity, whichmeans that they are active against awide range ofmicroorganisms including
both pathogenic and nonpathogenic strains.
Moreover, many microorganisms are able to produce enzymes that neutralize antimi-
crobial compounds. Others can acquire resistance to weak, short-term or repeated ex-
posure to antibiotics. Antibiotic resistance will, in the very near future, leave healthcare
1
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professionals without effective therapies for bacterial infections. As an example, it is
now estimated that about half of all Staphylococcus aureus strains found in many medical
institutions are resistant to antibiotics such as methicillin (Roder et al., 1989).
Consequently, thepriority for thenextdecades shouldbe focusedon thedevelopment of
alternative drugs and/or the recovery of natural molecules that would allow the consistent
and proper control of pathogen-caused diseases. Ideally, these molecules should be as
natural as possible, with a wide range of action over several pathogens, easy to produce,
and not prone to induce resistance.
1.2 The importance of the innate immune response in living or-
ganisms
Living organisms are exposed daily to microbes including pathogens, and in order to de-
fend themselves against the abrasive environment, they have developed potent defense
mechanisms that are part of innate and adaptive immunity. In invertebrates, only innate
immunity, recognized as an ancient mechanism, is present. In vertebrates, defense re-
actions rely on both innate and adaptive immunity (Hoffmann et al., 1999). The innate
immune systemprovides a first line of host defense againstmany commonmicroorganisms
and is essential for the control of common bacterial infections (Medzhitov and Janeway,
2002). All metazoans have inborn defense mechanisms that constitute innate immunity
(Ezekowitz and Hoffmann, 1996).
There are a number of components of host innate immunity. These include physical
elements such as the barrier formed by the epithelial cells, and local production of proteins,
like cytokines, as well as neutrophil recruitment (Nemes and Steinert, 1999; Neutra et al.,
2001). Other components of the innate immune response include the complement sys-
tem, scavenger cells (macrophages and neutrophils), and the production of antimicrobial
substances, which are mainly peptides or polypeptides (Krisanaprakornkit et al., 2000).
Our understanding of innate immune mechanisms has recently undergone a major
advance with the discovery of toll-like receptors (TLRs). These are a series of germ-
Chapter 1. Introduction 3
line encoded pattern-recognition receptors (PRRs) which recognize conserved pathogen-
associated molecular patterns (PAMPs) (Akira and Sato, 2003). PRRs can act to enhance
the binding of PAMPs to cell surface receptors, to activate inflammatory responses or to
induce phagocytosis of the microbe, or to effect a combination of these actions (Barton
and Medzhitov, 2002; Takeda and Akira, 2003; Underhill and Ozinsky, 2002). Intracellular
PRRs called NODs have been described; these are involved in generating an inflammatory
response to specific components of the bacterial cell wall (Inohara andNunez, 2003). These
PRRs provide the body with the ability to detect and respond to a wide variety of bacteria
found in various compartments of the body.
Certainly, all the components of innate immunity mentioned above play a role in host
defense. The overall response is the result of the complex interplay between a number
of different bacterial molecules reacting with their corresponding receptors on the cell
surface. However, an essential element to the concept of innate immunity is immediate
responsiveness to danger. Recruitment of neutrophils andmacrophages takes time, usually
hours, whereas pathogenic bacteria might replicate rapidly in vivo. In a complex system
such as in humans, an invading microorganism can simply be eliminated by this primary
reaction - the innate response - without requiring an activation of the adaptive immunity,
the next step in this complex cascade (Bals, 2000). Antimicrobial peptides (AMPs) have
emerged as key elements for inhibition of microbial proliferation prior to recruitment of
cellular immune defense elements.
1.3 Antimicrobial peptides (AMPs)
Antimicrobial peptides (AMPs) are ubiquitous molecules as they are found in microor-
ganisms as well as in plants (Cammue et al., 1992), invertebrates and also vertebrates
(Lehrer and Ganz, 1996; Schro¨der, 1999; Zasloff, 2002). They represent the first line of
defense against pathogens acting as effector molecules of innate immunity. The emergence
of resistance to commonly used antibiotics has stimulated the search for new naturally
occurring bactericidal and fungicidal agents that may have clinical utility.
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1.3.1 Discovery of AMPs
In the late 1870s scientists were searching for an agent to kill microbes without causing
unacceptable damage to the hosts. In the search for this agent, Ehrlich started to work
on mammalian granulocytes and noted the different staining characteristics of these cell
(Spitznagel, 1997). In 1890s, Petterson found that aqueous extracts of pus from human
emphysema had antimicrobial activity (Spitznagel, 1997). In following decades, especially
after the discovery of penicillin, lots of antimicrobial peptides were isolated, such as tyroci-
dine and gramicidin antimicrobial peptides from Bacillus brevis, mellitin from bee venom,
and cationic antimicrobial proteins from rabbit (Zeya and Spitznagel, 1969). However, an
important facet of this defense mechanismwas revealed two decades ago by the discovery
of cecropins, inducible antimicrobial peptides in the giant silk mothHyalophora cecropia. In
1981, Boman and his associates reported that these widespread biochemical defense pep-
tides act as antibiotics (Steiner et al., 1981). At first it was thought that these antimicrobial
peptides were unique to insects, but later they were isolated from other animals including
mammals revealing that these peptides were widely distributed in the animal kingdom
and provide enormous survival benefits to the host (Zasloff, 1992). Because these peptides
are very potent against bacteria, but have no toxic or hemolytic effect on host cells, and
have a wide taxonomic distribution, their discovery led to the start of a new era in studies
of animal antimicrobial peptides (Boman, 1995).
1.3.2 Classification of AMPs
A large number of AMPs has been found in insects, amphibians and mammals. AMPs are
widely distributed in nature and represent an ancient mechanism of host defence. More
than 1700 such AMPs have been discovered, and an updated list can be found at the web-
site: http://research.i2r.a-star.edu.sg/Templar/DB/ANTIMIC/. Most of the antimicrobial
peptides are cationic although some anionic peptides have been reported (Fales-Williams
et al., 2002).
On the basis of their structural features, cationic peptides can be divided into four
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classes in Table 1.1 (Tossi and Sandri, 2002; Zasloff, 2002):
Table 1.1: AMPs—structural classes
Cl. Structure Example Origin
1 Linear, α-helix Magainin Frog
Clavanin Tunicate haemocytes
Linear, 2 α-helix Cecropin A Insect haemolymph
2 Extended, high Bactenecin7 (Proline-rich) Bovine neutrophils
proportion of a single Holotricin3 (Glycin-rich) Insect haemolymph
amino acid Histatin (Histidine-rich) Primate saliva
Indolicidin (Tryptophan-rich) Bovine neutrophils
3 1-disulfate, loop Bactenecin Bovine neutrophils
Ranalexin Frog skin
4 2-disulfide, β-sheet Protegrins Pig leukocytes
Tachyplesins Horseshoe crab haemocytes
3-disulfide, β-sheet HNPs (α-defensin) Human neutrophils
HBDs (β-defensin) Human skin
3-disulfide, β-sheet Phormecin(Insect defensin) Insect haemolymph
+α-helix
3-disulfide, β-sheet Thionins (γ-thionin) Plant tissue
+ 2 α-helix
4-disulfide, β-sheet AFP-1 Plant tissue
+ α-helix MGD-1 Mollusc haemolymph
(1) linear peptides forming-helical structures. This family includes the cecropins from
the haemolymph of insects (Hultmark et al., 1980; Andreu and Rivas, 1998; Boman,
1998; Zheng and Zheng, 2002), the magainins isolated from Xenopus skin (Zasloff, 1987;
Bechinger et al., 1993; Simmaco et al., 1998), and the histone derived compounds isolated
from fish epithelia (parasin) (Park et al., 1998), the cytoplasm of murine macrophages
(Hiemstra et al., 1993) and human wound fluids (Frohm et al., 1996);
(2) cysteine-rich open-ended peptides containing single or several disulfide bridges
(Lehrer and Ganz, 2002). This family mainly contains the thionins isolated from plants
(Bohlmann et al., 1998) and the defensins, a highly complex group of 4-kDa open-ended
cysteine-rich peptides arranged with different structural motifs. Defensins have been
isolated from mammals, insects and plants and they serve as effector molecules of innate
immunity, providing an efficient initial defence against infectious pathogens (Ganz, 1999;
Selsted et al., 1984). Many defensin-like antimicrobial peptides have been identified from
scorpions (Cociancich et al., 1993; Ehret-Sabatier et al., 1996) and mussels (Charlet et
al., 1996). In mammals, α- and β-defensins are characterized by an antiparallel-β sheet
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structure, stabilized by three disulfide bridges (Zasloff, 2002). Some of them naturally
exist as cyclic molecules such as the θ-defensins (Tang et al., 1999; Lehrer and Ganz, 2002).
(3) molecules rich in specific amino acids such as proline, glycine, histidine and tryp-
tophan. Those proline- and glycine-rich are mostly from insects and active against Gram-
negative bacteria (Bulet et al., 1999; Otvos, 2000); while those enriched in histidine are
particularly basic, mostly from mammals (Pollock et al., 1984) and primarily directed
against fungal pathogens (Tsai and Bobek, 1998). Only two peptides enriched in tryp-
tophan residues have been described, both derived from porcine cathelicidin precursors
(Schibli et al., 2002).
1.3.3 The importance of AMPs in human skin
As described above, more than 1700 of naturally occurring peptide antibiotics have been
discovered based on their ability to inhibit the growth of microbial pathogens. These
AMPs participate in the innate immune response by providing a rapid first-line defence
against infection. Current evidence shows that cathelicidins and defensins act as both
natural antibiotics and as signalling molecules that activate host cell processes involved
in immune defence and tissue repair. Alterations in the expression pattern of AMPs have
been associated with a variety of pathological processes. Ongoing and future studies are
likely to implicate AMPs in several unexplained human inflammatory disorders and to
provide novel therapeutic approaches for the treatment of these diseases.
AMPs play also a magic role in the skin defense system. The skin serves as a protective
barrier between internal organs and the outside environment. Skin epithelium functions
naturally as a physical barrier. It has an active immunological role in antigen processing
and presentation as well as production of cytokines and defense molecules such as AMPs.
The number of reports demonstrating the presence and upregulation of antimicrobial
peptides in human skin is increasing and reflects the significance of these peptides in
cutaneous innate immunity (Bardan et al., 2004).
Various AMPs, like the cathelicidin LL-37/hCAP18, β-defensins hBD1–4, RNase-7, pso-
riasin and dermcidin have been found in human skin (Frohm et al., 1997; Harder et al.,
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1997; Harder et al., 2001; Harder and Schro¨der, 2002; Gla¨ser et al., 2005; Schittek et al.,
2001), protecting skin against invading microorganisms (Peschel, 2002; Bardan et al., 2004;
Harder and Schro¨der, 2005). These peptides are produced by epithelial cells and have
been proposed to provide a first line of defence against infection by acting as ’natural anti-
biotics’. The human LL-37/hCAP18, HBD2, HBD3, and RNase-7 are expressed by human
skin keratinocytes at sites of inflammation in disorders such as psoriasis, nickel contact
dermatitis, systemic lupus erythem andNetherton syndrome and function primarily in the
response to injury (Frohm et al., 1997; Harder et al., 1997; Harder et al., 2001; Harder and
Schro¨der, 2002). The dermcidin is specifically and constitutively expressed in the sweat
glands, secreted into the sweat and transported to the epidermal surface (Schittek et al.,
2001). Recently, the S100A7/psoriasin was characterized as a new generation of AMPs in
human healthy skin (Gla¨ser et al., 2005).
Interestingly, the activity of AMPs is not limited to the killing of microorganisms.
In addition, several other actions have been identified. In fact, their multiple roles as
mediators of inflammation with effects on epithelial and inflammatory cells has been
demonstrated. They are involved in such diverse processes as proliferation, immune
induction, wound healing, cytokine release, chemotaxis, protease/antiprotease balance,
and redox homeostasis (Ganz, 2002; Cole et al., 2003; Com et al., 2003; Liu et al., 2003).
1.4 The barrier function of human skin
The outermost skin layer, the epidermis, provides the first line of defense against
pathogens. Historically, keratinocytes, which form 95% of all epidermal cells, were be-
lieved to function purely inmaintaining the structure of the epidermis via their production
of cytokeratins and in the maintenance of a physical barrier to a variety of exogenous mi-
croorganisms. The stratified epithelia is the most superficial layer of the skin and is
subdivided into five layers, the stratum germinativum, the stratum spinosum, the stratum
granulosum, the stratum lucidum and the stratum corneum. The stratum corneum, the
final product of epidermal cell differentiation, forms a protective barrier from physical,
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chemical and mechanical insults including microorganisms whilst protecting body home-
ostasis such as temperature regulation and prevention of fluid loss (Nemes and Steinert,
1999).
A major portion of the barrier function of skin is due to the presence of the cornified
cell envelope (CCE), which is a specialized structure formed immediately beneath the
plasma membrane of keratinocytes during the last stage of their differentiation (Steinert
and Marekov, 1999). The mechanical behavior of the CCE is characterized by its rigidity
and insolubility (Regnier et al., 1993; Nemes and Steinert, 1999).
1.4.1 The cornified cell envelope (CCE)
The stratum corneum composed of multiple layers of flattened dead cells, forms a tough,
impenetrable barrier that shields the underlying living cells from hazards of the surround-
ing environment (Fuchs et al., 1994; Polakowska and Haake, 1994; Ishida-Yamamoto and
Lizuka, 1998; Steinert and Marekov, 1999). Corneocytes are the end-products of the ter-
minal differentiation pathway of keratinocytes in these tissues. Their organelles, having
broken down, consist simply of a keratin filament matrix encased within the CCE. The
CCE is assembled late in the pathway when it replaces the cytoplasmic membrane, and
consists of a layer of cross-linked protein coated with covalently bound lipids (Swartzen-
druber et al., 1987). Among themanymorphologic changes that occur in normal epidermis
during the transition from granular to cornified cells are the dissolution of the nucleus and
other organelles, the aggregation of the keratin intermediate filament (IF) network into
macrofibrils, and the formation of a cornified cell envelope consisting of loricrin, the small
proline-rich proteins, involucrin, and other proteins that are crosslinked by transglutami-
nases in the stratum corneum (Nemes and Steinert, 1999; Presland and Dale, 2000; Kalinin
et al., 2001). However, the maintenance of barrier functions depends on epithelial interac-
tions with the dermis via the continuous process involving keratinocyte proliferation and
terminal differentiation.
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1.4.2 The epidermal differentiation complex (EDC)
In humans, at least 47 genes specially involved in the differentiation process have been
discovered and are clustered within the epidermal differentiation complex (EDC) in chro-
mosome 1q21 (Volz et al., 1993; Mischke et al., 1996). They encode structural as well as
regulatory proteins which cooperate during epidermal differentiation. They also show
evolutionarily conserved structural relationship together with functional interdependence
of the encoded proteins and can be grouped into three structurally related gene families
(Marenholz et al., 2001).
The members of the first family encode the CCE precursor proteins. They include
involucrin, loricrin, small proline rich proteins (SPRR) (reviewed by Tesfaigzi and Carlson,
1999) and 18 late envelope proteins (LEP) (Marshall et al., 2001) that are crosslinked by
the action of keratinocyte transglutaminase at the cell periphery (review by Grenard et al.,
2001). Loricrin, involucrin, SPRR, LEP and the distantly related NICE-1 (Marenholz et al.,
2001) are encoded by geneswith similar structures. The proteins encoded have homologies
in the terminal protein domains and contain a variable number of internal tandem repeats
specific for each protein, and are major precursors for the building of the CCE.
The second family encode S100 calcium-binding proteins (Schafer andHeizmann, 1996;
Heizmann et al., 2002). The S100 proteins comprise a multigene family of low molecular
weight proteins that engage in multiple functions in a wide variety of cell types and
tissues (Heizmann et al., 2002; Donato, 2003). S100 proteins are characterized by common
structural motifs including two EF hands (helix-loop-helix calcium-binding domains) that
are separated by a hinge region and flanked by amino- and carboxy-terminal domains.
The canonical C-terminal EF-hand binds calcium with a 100-fold higher affinity than
the N-terminal, non-conventional, EF-hand (Gribenko and Makhatadze, 1998; Zimmer
et al., 2003). They are regulatory proteins primarily involved in different steps of the
calcium signal transduction pathway regulating cell shape, cell cycle progression, and
differentiation (Eckert et al., 2004). Among the 21 S100 proteins that have been cloned
to date, eleven, including S100A2, S100A3, S100A4, S100A6, S100A7, S100A8, S100A9,
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S100A10, S100A11, S100A12, and S100A15, are expressed in the human epidermis or in
cultured keratinocytes (Boni et al., 1997; Xia et al., 1997; Broome et al., 2003). They may
play a role in the pathogenesis of epidermal diseases such as psoriasis, skin cancer, and
skin inflammation (Eckert et al., 2004). Originally characterized as a marker of psoriasis,
S100A7 (also called psoriasin) overexpression is seen in many inflammatory skin diseases,
including atopic dermatitis, mycosis fungoides, Darrier’s disease, and inflammatory lichen
sclerosus and atrophicus (Madsen et al., 1991; Algermissen et al., 1996; Broome et al., 2003).
More interestingly, psoriasin was found to confer potent bactericidal activity against E.coli
in skin (Gla¨ser et al., 2005).
The third family of genes encode intermediate filament-associated S100 fused-type
proteins (SFTP family). The proteins encoded combines EF hands and internal tandem
repeats. They comprises profilaggrin (Fleckman et al., 1985) , trichohyalin (Lee et al.,
1993), and c1orf10 (Xu et al., 2000). This family also includes repetin (Krieg et al., 1997) and
hornerin (Makino et al., 2001) in mice. The SFTPs are synthesized in the granular layer of
the epidermis and conjoin with the keratin filaments of keratinocytes during cornification
(O’Guin et al., 1992; Resing et al., 1993). Functionally, they are associated to keratin
intermediate filaments and partially crosslinked to the CCE, as is summarized in the next
section.
1.4.3 The functions of the SFTP family members
Profilaggrin (PFLG) is a major protein component of the keratohyalin granules of mam-
malian epidermis. It is initially expressed as a large polyprotein precursor which is sub-
sequently processed to functional filaggrin (FLG) units in the terminal phase of epidermal
differentiation (Resing et al., 1995). The FLGs show wide species variations and their
aberrant expression has been implicated in a number of keratinizing disorders (Baden et
al., 1974; Holbrook et al., 1982; Sybert et al., 1985). PFLG is a large, highly phosphorylated,
insoluble protein consisting of multiple (10-12 in human, 20 or more in rodents) FLG units
joined by linker peptides. PFLG is expressed in the granular layer where it is localized
within electron-dense nonmembrane bound keratohyalin granules (Presland and Dale,
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2000). This sequestration into keratohyalin is believed to protect the epithelial cell from
thedeleterious effects of premature keratin aggregation byFLG (Dale et al., 1997; Kuechle et
al., 1999; Presland et al., 2001). Recent studies have shown that the profilaggrin N-terminal
region (which contains the calcium-binding elements) is specifically removed from the
protein by proteolysis and localizes to the nuclei of keratinocytes destined to undergo
terminal differentiation. FLG binds to cytoplasmic keratin IFs to form the macrofibrils
that are retained in cornified cells, whereas the N-terminal peptide localizes to nuclei of
epidermal granular and transition cells (Ishida-Yamamoto et al., 1998; Presland and Dale,
2000). Therefore, PFLG processing provides a potential link between two major events
of terminal differentiation: the aggregation of keratin filaments and nuclear dissolution
(Pearton et al., 2002).
Trichohyalin (THH) is expressed in specialized epithelia that are unusually mechani-
cally strong, such as the inner root sheath cells of the hair follicle (Rothnagel and Rogers,
1986). In pig, tongue THH is sequentially subjected to post-syntheticmodifications by pep-
tidylarginine deaminases, which convert many of its arginines to citrullines, and by trans-
glutaminases, which introduce intra- and interprotein chain cross-links, to form highly
cross-linked rigid structures in the cells (Tarcsa et al., 1997). In the mouse hair follicle,
trichohyalin is a multi-functional cross-bridging protein that functions in the inner root
sheath and perhaps in other specialized epithelial tissues by conferring to and coordinat-
ingmechanical strength between their peripheral cell envelope barrier structures and their
cytoplasmic keratin filament networks (Steinert et al., 2003).
C1orf10 is highly expressed only in the esophagus of normal adult tissues and was
undetectable in a total of 15 other tissues examined (Xu et al., 2000). The expression of
C1orf10 might be unique to esophageal cells and that loss of its expression may play a role
in the development of esophageal cancer (Yagui-Beltran et al., 2001).
Other SFTP members have also been identified in mice. The hornerin (HRNR) protein
was detected in keratohyalin granules of epidermal granular cells together with profilag-
grin (Makino et al., 2001). The repetitive domain of HRNRwas found to be rich in glycine,
serine, and glutamine. HRNR was expressed highly in the tongue, esophagus, forestom-
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ach, and skin among the adult mouse tissues examined, all of them cornifying stratified
epithelium. In skin, HRNRwas expressed in the upper epidermis of newborn mouse skin,
as was profilaggrin, but the amount of hornerin mRNA was more than fourfold greater
than the amount of profilaggrin mRNA (Makino et al., 2003). Repetin (RPTN) is expressed
in the stratified internal epithelia of forestomach and tongue and to a lesser degree in nor-
mal skin epidermis, where it is restricted to the differentiated suprabasal cell layers (Krieg
et al., 1997). Increased expression of RPTN has been found in loricrin-deficient mice to
maintaining skin barrier function (Djian et al., 2000; Koch et al., 2000), which implies that
compensatory mechanisms exist in epithelia that can overcome the absence of involucrin.
Altogether, all SFTP genes share a common gene structure and all SFTP proteins
share similar structural characteristics. Human SFTP genes (profilaggrin, trichohyalin
and C1orf10), located in the EDC region, share the same genomic structure, which has
three exons and two introns with the typical GT-AG structure. The first exon is located in
the 3-terminal untranslated region while the second exon encodes the S100 domain. The
third exon is very big and encodes the most part of its protein including the EF-hand and
multiple tandem repeats. Therefore, these three proteins together with mouse repetin and
hornerin, have one S100 domain at the N terminus followed by the second Ca2+ binding
EF-hand domain and they are therefore thought to have evolved through fusion between
genes of the S100Ca2+-bindingproteins andgenes of cornified envelopeprecursor proteins.
1.5 Two emerging novel families of AMPs
Two emerging novel families of AMPs have been neglected, compared with the well
studied cathelicidin and defensins families.
The S100 proteins comprise a family of 21 low molecular weight (9-13 kDa) proteins
that are characterized by the presence of two calcium-binding EF-hand motifs (reviewed
by Eckert et al., 2004). Fourteen S100 protein genes are located within the epidermal
differentiation complex on human chromosome 1q21 and are expressed in normal and/or
diseased epidermis. They exist in cells as anti-parallel hetero- and homodimers and
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upon calcium binding interact with target proteins to regulate cell function. They have
also been associated with a large number of human diseases including inflammation,
Down’s syndrome, neurological disorders, cystic fibrosis, myocardial infarction, psoriasis,
and cancer (Heizmann et al., 2002). The structural organization of S100 genes is highly
conserved (Zimmer et al., 1996; Nakamura et al., 1998). The typical gene, with some
notable exceptions such as S100A4, S100A5, and S100A14, consists of three exons, where
the first exon has the 5’ untranslated sequences, the second exon contains ATG and codes
for the N-terminal EF-hand, and the third exon encodes the carboxy-terminal canonical
EF-hand (Heizmann et al., 2002; Pietas et al., 2002). The amino-terminal loop in exon 2
is S100 specific, with a lower Ca2+-binding affinity than the canonical Ca2+-binding loop
within the carboxy-terminal EF-hand of exon 3. The S100 genes are found in all vertebrates
examined so far such as human, bovine, porcine, rat, mouse, rabbit, avian, and frog (Kube
et al., 1991; Zimmer et al., 1996; Nakamura et al., 1998).
Two S100 proteins, calprotectin and S100A7/psoriasin have been associated with an-
timicrobial activity (Steinbakk et al., 1990; Miyasaki et al., 1993; Nisapakultorn et al., 2001;
Gla¨ser et al., 2005). Calprotectin is a noncovalently complexed heterodimer of two small
anionic proteins S100A8-S100A9 (Johne et al., 1997) and is constitutively expressed in squa-
mous mucosal epithelial cells (Wilkinson et al., 1988). Psoriasin is key to the resistance of
skin against E. coli (Gla¨ser et al., 2005). Both calprotectin and psoriasin bind zinc, thereby
depriving microorganisms of this essential nutrient as an antimicrobial mechanism.
The family of kazal-type protease inhibitors, belongs to MEROPS inhibitor family I1,
clan IA (Rawlings et al., 2004). They inhibit serine peptidases of the S1 family (InterPro
accession No. IPR001254), such as trypsin and elastase (Rawlings et al., 2004), and are
named serine protease inhibitor, kazal-type (SPINK). The Kazal-type motif is character-
ized by six cysteine residues distributed over a region of about 40–60 amino acids with
other residues conserved especially adjacent to Cys3 and a tyrosine located between Cys3
andCys4, whichmakes it different from the Kunitz-type serine protease inhibitor sequence
motif (Rawlings et al., 2004; Williamson et al., 1984). These proteins contain between 1
and 7 Kazal-type inhibitor repeats (Williamson et al., 1984; Laskowski et al., 1987). There
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are a number of inherited diseases that are attributable to abnormalities in peptidase in-
hibitors. These include forms of emphysema, epilepsy, hereditary angioneurotic oedema
and Netherton syndrome (Lomas et al., 2002; Ritchie, 2003; Lehesjoki, 2003; Bitoun et al.,
2002). An imbalance between the active enzymes and their natural inhibitors leads to
the accelerated destruction of connective tissue, which is associated with the pathology of
diseases such as arthritis, cancer, multiple sclerosis and cardiovascular diseases (Peress et
al., 1995; Wernicke et al., 1996; Steinman, 1996). The potential for using specific enzyme
inhibitors as therapeutic agents to redress this balance has led to intensive research focused
on the design, synthesis and molecular deciphering of low-molecular-mass inhibitors of
this family of proteins (Johnson et al., 1987; Bottomley et al., 1998; Ahrens et al., 1996).
However, PSKP-1, one SPINK isolated from the skin of Phyllomedusa sauvagii, shows in-
hibitory activity against a serum prolyl endopeptidase, but is unable to inhibit trypsin,
chymotrypsin, V8 protease, or proteinase K (Gebhard et al., 2004). More interestingly,
PSKP-1 can be rendered active against trypsin by active-site site-specific mutagenesis, has
bactericidal activity, and induces agglutination of red cells at micromolar concentrations
(Gebhard et al., 2004).
1.6 Objective of this study
Our research group recently has isolated two antibacterial peptides from skin-derived
stratum corneum extracts, one with a N-terminal protein sequence similar to SFTPs (ten-
tatively termed SFT-AMP) and another with homology to kazal-type protease inhibitors
(tentatively termed KT-AMP) (Fig. 1.1). The main objective of the study is to characterize
and clone these novel AMPs. In detail, our aims are
1) to identify and characterize the human genes encoding for KT-AMP and
SFT-AMP;
2) to resolve the related potential gene clusters expressed in the epidermis;
3) to reveal potential control elements and signaling pathways governing ex-
pression of the gene cluster;
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4) to uncover genes and processes implicated in skin diseases or tumors asso-
ciated with the two gene clusters.
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Figure 1.1: Preparative C8 RP-HPLC analysis of heparin-bound proteins from pooled
stratum corneum extracts of healthy person’s heel callus. Bars indicate the E. coli-killing
activity of HPLC fractions. Two fractions marked with KT and SFT contain the novel
antimicrobial peptides KT-AMP and SFT-AMP, which comprise the main emphasis in
this study. Other HPLC fractions contain already known antimicrobial proteins such as
psoriasin (P), lysozyme (L) and RNase-7 (R).
Chapter 2
Materials and Methods
2.1 Patients
The cDNA generated from skin biopsies of different patients was kindly provided by
Dr. Regine Gla¨ser (Hautklinik Kiel). A total of 17 unrelated individuals were investigated
with basal cell carcinoma (BCC), squamous cell carcinoma (SCC), precancerous lesions or
psoriasis vulgaris from the north of Germany (Table 2.1).
Table 2.1: Characteristics of patients
Patient Sex Age Localization Diagnose
1b W 90 lower leg Basal Cell Carcinoma
14b M 51 temporal Basal Cell Carcinoma
43b M 83 temporal Basal Cell Carcinoma
56b M 74 preauricular Basal Cell Carcinoma
95b M 69 cheek Basal Cell Carcinoma
63b M 85 cheek Squamous cell carcinoma
73b M 81 capillitium Squamous cell carcinoma
86b M 68 helix Squamous cell carcinoma
109b M 86 shoulder Squamous cell carcinoma
130b M 88 helix Squamous cell carcinoma
28b M 94 mast Precancerous Lesions
91b M 78 shoulder Precancerous Lesions
111b M 81 retroauricular Precancerous Lesions
Each tumor specimen or psoriasis lesions was divided into matched fractions for RNA
isolation. All subjects were informed about the contents and aims of the study and gave
16
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their written consent. All humanmaterials were collected in compliance with the laws and
guidelines of the ethics committee of the medical faculty of Christian-Albrechts University
Kiel, Germany.
2.2 Materials
The cell line HaCat was obtained from the Deutsches Krebsforschungszentrum (Heidel-
berg, Germany). 6-well and 12-well culture Plates were obtained from Becton Dickinson
(Heidelberg, Germany). Cell culture flasks (200 ml; 75 cm3) were obtained from Sarstedt
(Nu¨mbrecht). DMEM (Dulbecco‘s modified Eagle Medium) and FCS (fetal calf serum)
were obtained from Cell Concepts (Umkirch, Germany). Dulbecco‘s PBS was obtained
from PAA Laboratories GmbH (Co¨lbe, Germany). Blue-Dextran and dNTPs were ob-
tained from Pharmacia (Freiburg, Germany). Agarose was obtained from Biozym Hess
(Oldendorf, Germany). Acetonitril, H2O (forHPLC) andmethanol was obtained fromPro-
mochem (Wesel, Germany). LightCycler-FastStart DNAMaster SYBRGreen I and Stericup
Filtrations system was obtained from Roche (Mannheim, Germany). Glycogen proteinase
K was obtained from Boehringer (Mannheim, Germany). Millipore YM 3 and YM 30
(3 kDa and 30 kDa) were obtained from Millipore GmbH (Eschborn, Germany). Glycerol
was obtained from USB (Cleveland). Sojamehl-Pepton was obtained from Unipath LTD.
(Hampshire). Superscript Reverse Transcriptase was obtained from Invitrogen. Nitrocel-
lulose and blotting paper were purchased from Schleicher and Schuell (Dassel, Germany).
Restriction endonucleases were from New England Biolabs. The following materials were
obtained from Gibco (Eggenstein, Germany): Agarose (ultrapure), Bacto-Trypton, Bacto-
Yeast-extract, EDTA, L-Glutamin, Penicillin-Streptomycin-solution, Trypsin and Trypsin-
EDTA. The followingmaterials were obtained from Sigma (Deisenhofen, Germany): Agar,
Bovines Serum Albumin (BSA), Bromphenolblue, Chloroform, Formamid, DEPC, DMSO,
DTT, EpiLife, Ethidiumbromid, Gelatine, Glutaraldehyde, Isopropanol, L-Tryptophan,
Magnesiumchlorid (MgCl2), β-Mercaptoethanol, Tween, Xylencyanol. The carrier protein
keyhole limpet hemocyanin (KLH) was purchased from Pierce Chemical Company. All
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other chemicals unmentioned here were of analytical grade and purchased from Merck
(Darmstadt, Germany).
2.3 Tissues and RNA preparation
Total RNAs were isolated from normal human skin, larynx, pharynx, adenoid, polyp,
tonsil, tongue, psoriasis lesions and cultured keratinocytes by using TRIzol reagent (Invit-
rogen). All other RNAswere purchased fromClontech. The samples were stored at−80◦C
until use.
2.4 Cell Culture
Primary human foreskin keratinocytes were prepared from a pool of neonatal foreskins
obtained from routine surgery using the Rheinwald-Greenmethod (Rheinwald andGreen,
1975). Keratinocytes were isolated by using dispase incubation of foreskin tissue to allow
for dermalepidermal separation. Epidermal specimens were trypsinized and plated on
standard tissue culture dishes. Cells were maintained in EpiLife media (Sigma) supple-
mentedwith 10% fetal calf serum containing 10 U/µl penicillin and 0.1 µg/µl streptomycin
(Life Technologies). The second passage cells weremaintained and utilizedwhen 75% con-
fluent. Cells were separated to 6-well plates and then stimulated with 1.7 mM Ca2+ or
10−7 M retinoic acid (RA) (Sigma) for the indicated time periods. In some cases cells were
treatedwith 0.5 µg/µl of PD98059, a potent inhibitor of theMAPKkinase (MEK1/2) (Favata
et al., 1998), 0.5 µg/µl of SB203580 or SB202190, an inhibitor of the p38 kinase (Cuenda et
al., 1995), SB202474, a p38 inactive analog or/and 2.5 µg/µl of SP600125, an inhibitor of the
JNK kinase obtained from Calbiochem in 50% DMSO. Each experiment was performed at
least in twice.
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2.5 Conventional RT-PCR
The cDNAwas synthesized from 2 µg of total RNAwith the SuperScript II system (Invitro-
gen). A total of 2 µg of total RNA was treated with RNase-free Dnase (Roche Diagnostics,
Mannheim, Germany) and reverse transcribed with an oligo(dT)18 primer and Superscript
II RNaseH− reverse transcriptase (Invitrogen) in a 20 µl reaction volume under the fol-
lowing conditions: 60 min at 42◦C in 50 mM Tris/HCl, pH 8.3, containing 75 mM KCl,
3 mMMgCl2, 10 mM dithiothreitol and 0.5 mM dNTPs, followed by enzyme inactivation
for 15 min at 70◦C. The reaction mixture was diluted 10 times with H2O for PCR ex-
periments. All gene-specific PCR primers (Table 2.2) were designed based on PRIMER3.0
(http://frodo.wi.mit.edu) to amplify products in the range 150 to 370 bp and to span the first
exon-intron boundary. The conditions for PCR were optimized in the Robocycler gradient
96 (Stratagene) and subsequently used for the following conventional PCR and Real-time
quantitative RT-PCR. The GAPDH sequence and a cloned corresponding cDNA sequence
were used for normalization and to calibrate standard curves, respectively. Conventional
PCR was carried out with Advantage 2 Polymerase Mix (Clontech) using a ’touch-down’
PCR strategy.
For THHL1, THH, PFLG, IFPS and C1orf10, the thermal cycling conditions comprised:
firstly 1 min at 95◦C followed by 5 cycles at 95◦C for 20 s, 68◦C for 45 s; 5 cycles of 95◦C
for 20 s, 66◦C for 20 s, 68◦C for 45 s; and finally 32 cycles of 95◦C for 20 s, 64◦C for 30 s,
68◦C for 45 s.
For RPTN, the thermal cycling conditions comprised: firstly 1 min at 95◦C followed by
5 cycles at 95◦C for 20 s, 72◦C for 45 s; 5 cycles of 95◦C for 20 s, 70◦C for 45 s; and finally
32 cycles of 95◦C for 20 s, 68◦C for 45 s.
For HRNR, SPINK6, SPINK7 and SPINK8, the thermal cycling conditions comprised:
firstly 1 min at 95◦C followed by 5 cycles at 95◦C for 20 s, 68◦C for 45 s; 5 cycles of 95◦C
for 20 s, 66◦C for 20 s, 68◦C for 45 s; and finally 32 cycles of 95◦C for 20 s, 64◦C for 45 s,
68◦C for 45 s.
For SPINK9, the thermal cycling conditions comprised: firstly 1 min at 95◦C followed
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by 5 cycles at 95◦C for 20 s, 72◦C for 45 s; 35 cycles of 95◦C for 20 s, 70◦C for 45 s; and
finally 72◦C for 10 min.
Specificity of the resulting PCR products was verified by purificating the amplified
fragments with the QiaQuik spin PCR purification kit (Qiagen), cloning into pGEM-T
vector (Promega) and subsequent sequencing.
Table 2.2: Primer sequences used for RT-PCR and quantitative real-time RT-PCR
Gene Forward Primer (5’ to 3’) Reverse Primer (5’ to 3’)
THHL1 GCTGCCCCACGTTCTACCT CATGAAGGACACAGGGCTGA
THH TGGTGAAGTGGGTTTACTTGAA GAAGCACAGCTCCAAATTCC
RPTN CAAGCAGGTTCACCCGTACTTG CATTTGGTCTCTGGAGGATGTCTC
HRNR CTCTGGTGAGCTAGGTTACTCA TGCAAGATGATATCCACAGTATCTG
PFLG GGCTCCTTCAGGCTACATTCTA ATCTGGATTCTTCAGGATTTGC
IFPS ACCAGGGTTCACTTAAACTTGCA ATGACATCCACTGTGTCTGGATC
C1orf10 GTTGACTTCAAAGATGCCTCAGT GTGGGGTTTCACAATCACATC
SPINK6 ACCTCAGCTGGACAAAGCAG TGGCAAGTCACCAAGAAACA
SPINK7 TGCTTGGCTAGCTCTGCATT AAAGCGCAAGAGGGAGATTG
SPINK8 CATATTCAGCCACCTCATCCAG AAGCAAGTGTAGTTACTCTGGTACCC
SPINK9 ACTTGCAACCATGTTCAGTATAGA AACTTTAGAACAGAAGAAGCAATCA
GAPDH CCAGCCGAGCCACATCGCTC ATGAGCCCCAGCCTTCTCCAT
Table 2.3: PCR conditions for each primer pair shown in Table 2.2
Gene cDNA amplicon(bp) Annealing Temp(◦C) Detection Temp(◦C)
THHL1 212 63 76
THH 178 63 78
RPTN 175 67 80
HRNR 215 61 79
PFLG 211 63 76
IFPS 211 64 80
C1orf10 160 63 84
SPINK6 322 63
SPINK7 341 63
SPINK8 367 63
SPINK9 175 62 78
GAPDH 360 66
2.6 Real-time RT-PCR
Quantitative real-time PCR was performed by using LightCycler (Roche) with the SYBR
Green I detection system (Roche) under the indicated optimized conditions in Table 2.3.
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For each gene, a primer pair flanking the first exon-intron boundary within each gene was
constructed and synthesized (Table 2.2). The cDNA equivalent to 10 ng of RNA served as
template for PCR in a volume of 10 µl. Each PCR mixture was prepared as follows: 6.4 µl
of water, 1.2 µl of MgCl2 (4 mM), 0.2 µl of each primer (4 µM), 1.0 µl of FastStart Master
SYBR Green I mixture. Samples were amplified in capillaries after initial denaturation
at 95◦C for 10 min for 45 cycles: 10 s of denaturation at 95◦C, 5 s of annealing at initial
68◦C (’touchdown’ of −1◦C/cycle to 62◦C) and 10 s of extension at 72◦C. SYBR Green I
fluorescence was measured at 72◦C at the end of each cycle.
Melting curves were generated after each run to confirm amplification of specific tran-
scripts (cooling of the samples at 65◦C for 15 s, heating at 0.2◦C/s to 95◦Cwith continuous
measurement of the fluorescence). The specificity of each gene products was verified by
sequencing. The housekeeping gene GAPDH (glyceraldehyde phosphodehydrogenase)
was amplified with each cDNA in a separate PCR to allow calculation of the relative tran-
scripts. The plasmid DNA with the corresponding insert was linearized with restriction
digestion and used for construction of standard curves. Exact quantification of the DNA
content was done on a GeneQuant II RNA/DNA calculator (Pharmacia Biotech). For stan-
dard curve acquisition, eight serial dilutions of linearized plasmid DNA were prepared,
representing 30−3.0×108 double-stranded DNA molecules.
2.7 In-Silico cloning of the novel human SFTP and SPINK genes
All the known SFTP protein sequences in human, mouse and rat were retrieved from
the NCBI database (www.ncbi.nlm.nih.gov), which included the five known SFTP
protein sequences, namely human profilaggrin (GenBank accession No. A45135), tri-
chohyalin (GenBank accession No. CAH70024), tumor-related protein (GenBank acces-
sion No. BC030807.1), mouse repetin (GenBank accession No. NP 033126) and hornerin
(GenBank accession No. NP 598459). All of the selected sequences were aligned
by the ClustalW algorithm on the EMBL server (www.ebi.ac.uk/embl/). The consen-
sus protein sequences were extracted and used as in silico probes to scan the human
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genome on the Ensemble Genome Browser (www.ensembl.org/Homo sapiens/). The
exon-intron boundaries of SFTP-like candidate genes were identified using FuzzyFinder
(http://www.cse.ucsc.edu/ kent/fuzzyFind/fuzzyFind.html). All the homolog SFTP se-
quences were used to recover the original ORFs for partial sequences of possible SFTP
genes. After duplicates were removed, all the different sequences were mapped to ge-
nomic locations using the BLAT algorithm (http://genome.ucsc.edu/cgi-bin/hgBlat). Like-
wise, the kazal-domain amino acid sequence was used as a query to screen the SPINK
family members.
The mouse and rat ortholog of human SFTPs and SPINKs were identified by tBLASTN
searches via the BLAT algorithm with the human SFTP/SPINK protein sequences against
the mouse and rat genome, respectively. The data obtainedwere contrastedwith gene pre-
dictions from themouse and rat Genome Initiative. Additionalmouse and rat SFTP/SPINK
homologies were identified by using the predicted mouse/rat SFTP/SPINK cDNA as in sil-
ico probe to scan the mouse/rat chromosome on the Ensemble Genome Browser. The
data obtained in the mouse and rat chromosome 18 were contrasted with gene positional
identity and exon/intron conservation to human SPINKs.
The signal anchor predictions were done using SignalP version 2.0
(http://www.cbs.dtu.dk); potential protein coding regions were identified with SMART
(http://www.smart.ox.ac.uk); potential post-translational modifications were determined
using NetPhos2.0 (http://www.cbs.dtu.dk) and NetNGlyc1.0 (http://www.cbs.dtu.dk); de-
termination of the modular structure of the proteins was performed using the PROFILES-
CAN Server from the Swiss Institute for Bioinformatics, the SMART (Simple Modular
Architecture Research Tool) site and the Conserved Domain Database at NCBI. Align-
ment of multiple predicted protein sequences was done by using ClustalW. The re-
sulting profile alignments were used to construct a phylogenetic tree with ClustalW
(http://bioweb.pasteur.fr/seqanal/interfaces/clustalw.html#trees) which was visualized
with the cladogram tree printer (http://bioweb.pasteur.fr/seqanal/interfaces/drawgram-
simple.html) and edited as a postscript file.
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2.8 5’ and 3’ Rapid Amplification of cDNA Ends (RACE)
Total RNAwas extracted fromhuman foreskin-derived keratinocytes usingTRIzol reagent.
After DNase I (Roche) treatment to exclude contamination with genomic DNA, 3 µg of
DNA-free total RNA was then used for first-strand cDNA synthesis for 5’RACE and
3’RACE respectively with SMART RACE cDNAAmplification Kit (Clontech) according to
the manufacturer’s protocol. The template RNA was digested with RNase H (Roche) and
the reaction mixture was diluted 10 times.
Table 2.4: Primer sequences used for 5’RACE
Primer Primer sequence
5’-RACE CDS Primer: 5’-(T)25N−1N-3’
THHL1-5’Race 5’-CTGTCCACTGACCATCTCCGGTGGTTG-3’
THHL1-5’RaceNest 5’-GTGGTTGCCTGAACATCCACATCATCTAGC-3’
THH-5’RACE 5’-AATGCTGCTCCATCACAATCATGAGAGAC-3’
THH-5’RaceNest 5’-CACAGCTCCAAATTCCCTTTCAAGGAGG-3’
RPTN-5’RACE 5 ’-GCAGGCTTGGACCAACTGGAACACCAAC-3’
RPTN-5’RaceNe 5’-AGCCGTGTTGGCCATAGTTGGGAGACTG-3’
HNR-5’RaceNest 5’-GACTGATGGGAGTCGGAGTTTTGCTCAC-3’
IFPS-5’RACE 5’-TGGTGTCGGTGACCACGCCTATGCTTC-3’
IFPS-5’RaceNest 5’-GCTGAGGACCTTGTTGCAGGCCATAGTCA-3’
SPINK6-5’Race 5’-AGGCACATTTATTGCCATATGTCTGGCCATC-3’
SPINK6-5’RaceNest 5’-GCCACAGTGTGGGTTAGATTCCCGAGTG-3’
SPINK6-3’RACE 5’-GCCAAACAGACGAAACAGATGGTTGACT-3’
SPINK6-3’RaceNest 5’-CACAGCTCCAAATTCCCTTTCAAGGAGG-3’
SPINK6-5’Race 5’-TGCCATCAGATCCACAAATTGGATCATAC-3’
SPINK6-5’RaceNest 5’-GCAGTCAACCATCTGTTTCGTCTGTTTGG-3’
SPINK7-5’RACE 5’-CTCAACACACAGAATGCAGGGATTATCATAGG-3’
SPINK7-5’RaceNest 5’-TAGGTTATAAAATTGGTGCCGCAGATGGGTTG-3’
SPINK8-5’Race 5’-ACACTCATTCTGGAAAGTGTGGCCATTTGAG-3’
SPINK8-5’RaceNest 5’-GGTGCTGTCACATTGGGGCAGTCTG-3’
SPINK9-5’Race 5’-TGCCATCAGATCCACAAATTGGATCATAC-3’
SPINK9-5’RaceNest 5’-GCAGTCAACCATCTGTTTCGTCTGTTTGG-3’
SPINK10-5’RACE 5’-CATTTCCATCAGATCCACAGTGAAGTGTGTAG-3’
SPINK10-5’RaceNest 5’-ATGGTACATGCCTCAGAATACCTGGTACACTG-3’
5’ RACE were performed essentially according to the Clontech SMART RACE cDNA
Amplification protocol. Reactions were set up as follows: 0.5 ng of adapted cDNA, 0.2 µM
10 × UPM primer, 0.2 µM gene-specific primer, 5 µl of 10 × reaction buffer (supplied with
Advantage polymerase), 0.2 mM dNTP, 1 µl of BD Advantage 2 Polymerase mix, in a
final volume of 50 µl. RACE PCR was performed on MJ Research Peltier Thermal cycler
PTC-200 and reaction cycles were as follows: 95◦C for 1min; 5 cycles of 95◦C for 30 s, 72◦C
for 3min; 5 cycles of 95◦C for 30 s, 70◦C for 3min; 25 cycles of 95◦C for 30 s, 68◦C for 3min;
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and a final extension of 10 min at 68◦C. Then, 0.5 µl of PCR products was employed as
template for a second round PCR (Nested PCR) under the following conditions: 1 min at
95 ◦C, 30 cycles of 20 s at 95◦C and 3 min at 70 ◦C, and a final extension of 10 min at 70 ◦C.
The gene-specific primers were generated with the predicted exons nucleotide sequences
above and listed in Table 2.4.
Table 2.5: Primer sequences used for 3’RACE
Primer Primer sequence
3’ RACE CDS Primer 5’-AAGCAGTGGTATCAACGCAGAGTAC
THHL1-3’Race 5’-GATGCCTCAGCTCCTGAGAAATGTCCTCTG-3’
THHL1-3’RaceNest1: 5’-GCATCAGGCCCAGAGCTTTGCAGTG-3’
THHL1-3’RaceNest2: 5’-CACAACCATATACCAGGGGACTTCCACTTG-3’
RPTN-3’Race 5’-CCTCCTCAAGCAGGTTCACCCGTACT-3’
RPTN-3’RaceNest1 5’-GGACACAGGACAGGCGAACCCATAA-3’
RPTN-3’RaceNest2 5’-AAGGGCTTTTGGTTCTTTGAGCAGCA-3’
RPTN-3’RaceNest3 5’-CCACTCCTCAAGGAACCCTAGATTTGGTG-3’
HRNR-3’Race 5’-AGTCTGGATCGAGACCATAACAAGAAAGTGGA-3’
HRNR-3’RaceNest1 5’-GATGACACTCACCAGCACCAAGAGGAAC-3’
HRNR-3’RaceNest2 5’-AGCATGAGTCTGCCTCCCGTCACTCTT-3’
HRNR-3’RaceNest3 5’-ATGGAAGTGGCTCAGGGCAAGATGGGTA-3’
HRNR-3’RaceNest4 5’-AACCATGATGGGGGAAGTTCTGGCTCA-3’
IFPS-3’Race 5’-ACCAGGGTTCACTTAAACTTGCA-3’
IFPS-3’RaceNest1 5’-GATGTCATCATGCATATGCTGGATCGAG-3’
IFPS-3’RaceNest2 5’-AGGCTTGAGTCAGTCCTCTGGGTTCG-3’
IFPS-3’RaceNest3 5’-TGGGCCAGGGTGAATCTCAACAAGTAGAG-3’
IFPS-3’RaceNest4 5’-GTTCGAGACCAGCCTGGCCAACATA-3’
IFPS-3’RaceNest5 5’-TCAGGAGGCTGAGGCAGGAGAATTG-3’
SPINK6-3’RACE 5’-GTGAGTTCCAGGACCCCAAGGTCTACTG-3’
SPINK6-3’RaceNest 5’-CCACACTGTGGCTCTGATGGCCAGA-3’
SPINK7-3’RACE 5’-GGTCAACCCCTGCCCTGGCTTATATCAAC-3’
SPINK7-3’RaceNest 5’-CAACCCATCTGCGGCACCAATTTTATAACCTA-3’
SPINK8-3’RACE 5’-CGATGTAAAATGTATATCCCACTGGACCCTGA-3’
SPINK8-3’RaceNest 5’-ATGCAGACTGCCCCAATGTGACAGCA-3’
SPINK9-3’RACE 5’-GCCAAACAGACGAAACAGATGGTTGACT-3’
SPINK9-3’RaceNest 5’-ACCACCAGGACAACAGAGATTTTGTCATC-3’
SPINK10-3’RACE 5’-ATTCAGTGTACCAGGTATTCTGAGGCATGTAC-3’
SPINK10-3’RaceNest 5’-TGGACTACACACTTCACTGTGGATCTGATGGA-3’
Thefirst strand cDNA(3’-ready cDNA) synthesis for 3’ RACEwasperformed according
to themanual of the SMART RACE cDNAAmplification Kit (Clontech) using the 3’-RACE
CDS Primer provided by the kit. The template RNA was digested with RNase H (Roche)
and the reaction mixture was diluted 10 times. Based on the sequence of the 5’ RACE
product, the sense gene specific primer was designed and synthesized (Table 2.5). The
3’ RACE PCR was carried out using primer and UPM under the following condition:
0.5 ng of adapted cDNA, 0.2 µM 10 × UPM primer, 0.2 µM gene-specific primer, 5 µl of
10 × reaction buffer (supplied with Advantage polymerase), 0.2 mM dNTP, 1 µl of BD
Chapter 2. Materials and Methods 25
Advantage 2 Polymerase mix, in a final volume of 50 µl. Reaction cycles were as follows:
95◦C for 1 min; 5 cycles of 95◦C for 30 s, 72◦C for 3 min; 5 cycles of 95◦C for 30 s, 70◦C for
3 min; 25 cycles of 95◦C for 30 s, 68◦C for 3 min; and a final extension of 10 min at 68◦C.
Then, 0.5 ul of PCR products was employed as template for a second round PCR (Nested
PCR) under the following conditions: 1 min 95 ◦C, 30 cycles of 20 s 95◦C and 3 min 70 ◦C,
and a final extension of 10 min at 70 ◦C. The PCR product was purified and cloned into
the pGEM-T cloning vector (Promega) followed by sequencing.
2.9 Long-distance PCR and the short-range PCR-walking strategy
BD Advantage 2 Polymerase mix was used for long-distance PCR of THHL1, SPINK6,
SPINK7-v2, SPINK8 and SPINK9. To determine the full-length sequences of human
repetin, ifapsoriasin and hornerin cDNA, an alternative approach was used, namely the
short-range PCR-walking strategy. Briefly, based on the newly defined 5’- and 3’-terminal
sequence, the middle part of each mRNA sequence was then predicted by in silico analysis
and used for primer design. Each primer pair (see appendix) was expected to produce
about 1 kb length of overlapping cDNA.
2.10 Subcloning and expression
2.10.1 Preparation of expression constructs
Six recombinant proteins were expressed in this study, which included human LEKTI-2,
LEKTI-3 and four hornerin fragments (HRNR1, residues 49–98; HRNR2, residues 1075–
1172; HRNR3, residues 2591–2662; and HRNR4, residues 2727–2850). The specific primer
pairs were listed in Table 2.6.
The regions of the corresponding cDNAs longer than that of the inserts coding for the
mature LEKTI-2, LEKTI3 and four hornerin fragments were synthesized by RT-PCR from
foreskin-derived keratinocytes RNA, as described. PCR was performed with Pfu DNA
polymerase (Promega). Except where indicated, PCR amplifications were performed in
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50 µl reaction volumes in the presence of the appropriate Tris-based buffer, using 2.5 U
polymerase, 100 mM each dNTP, 100 ng each primer and 50 ng cDNA template. The PCR
mixtures were denatured by heating at 98◦C for 30 s. Thirty cycles of amplification were
performed using the following conditions: 30 s at 98◦C; 45 s at Primer Tm−5◦C; 2 min at
72◦C.
Forgenerating the inserts, a secondnestedPCRwasperformedwith the specificprimers
pairs containing the Bgl II and Not I digestion sites under the following conditions: 45 s at
98◦C; 5 cycles (45 s at 98◦C; 45 s at 55◦C; 1 min at 72◦C). 25 cycles (45 s at 98◦C; 1 min
at 72◦C). The PCR products were gel purified, ligated into pGEM-T vector and verified
by sequencing. The inserts were cut with Bgl II and Not I, gel purified and cloned into the
expression vector pET-32a (Novagen) that had been double-digested with Bgl II andNot I.
The E. coli host strain BL21trxB(DE3)pLysSwas transformedwith the recombinant plasmid
constructs and used in expression studies. Recombinant colonies containing the cDNA
insert were identified by PCR using vector-specific (S-Tag promoter and T7 terminator)
primers. The resulting expression constructs, pET-LEKTI-2, pET-LEKTI3, pET-HRNR-1,
pET-HRNR-2, pET-HRNR-3 and pET-HRNR-4 were sequenced to confirm the reading
frame and the identity of the insert.
2.10.2 Induction and expression of the polyhistidine-tagged fusion protein
The expression construct was transformed in E. coli BL21trxB(DE3)pLysS cells (Novagen)
and grown overnight at 37◦C in TSB medium containing 100 mg/ml of carbenicillin,
34 mg/ml of chloramphenicol, 15 mg/ml of kanamycin. The overnight culture (5 ml)
was used for scaled expression (a volume of 1 L) the next day. When the optical density
at 600 nm reached 0.5, gene expression of the recombinant protein was induced with
1 mM isopropyl thio-β-D-galactoside (IPTG) for 3 h at 37◦C. After incubation, cultures
were harvested by centrifugation at 5000×g for 10 min at 4◦C and resuspended in 8 ml
of 1×LEW buffer (50 mM NaH2PO4, 300 mM NaCl, pH 8.0). Resuspended cells were
subjected to one cycle of freeze-thawing and disrupted by sonication in an ice bath until
the required visual viscosity was obtained. The separation of the cytoplasmic soluble
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Table 2.6: Primer sequences used for protein expression
PCR product Primer Primer sequence (5’ to 3’)
LEKTI-2 sense ACGGACACCAGGTCACTTCTTTTCCCTACATC
antisense TCTACATATGGTGATGAGTAGGCAATGTGGCA
lekti3 sense ACCTCAGCTGGACAAAGCAG
antisense TGGCAAGTCACCAAGAAACA
hrnr-1 sense CCTACAAGGCGTCATCACTGTCATCG
antisense TCAGTCCCAGGTTTAAGACTTCCTCTGACG
hrnr-2 sense CTCTACCCATGGGCAACACGGTTCT
antisense ATGCTGAGTGCAACCAGAGGACTGC
hrnr-3 sense CGGCCAGCGTGGGTCTGGGTCA
antisense TGTAGAACCATGCTGTCCTTGGCTACAGAAG
hrnr-4 sense AACCTTTGACCAGGAGGGATCTAGCA
antisense CAGTCTTTGGAAGGAACCCCATAACA
pET-LEKTI-2 sense ACTGAGATCTGGGTACCGACGACGACGACAAGACGAAACAGATGGTTGACTGC
antisense ATTTGCGGCCGCTCAACTTTTCCAAAATGTACAAA
pET-lekti3 sense ACTGAGATCTGGGTACCGACGACGACGACAAGCAGGTTGACTGTGGTGAGTTC
antisense ATTTGCGGCCGCTCAGCATTTTCCAGGATGCTT
pET-hrnr-1 sense ACTGAGATCTGGGTACCGACGACGACGACAAGGATGACACTCACCAGCACCA
antisense ATTTGCGGCCGCTCAAGACTGCCCTGACCCAGAC
pET-hrnr-2 sense ACTGAGATCTGGGTACCGACGACGACGACAAGACCCATGGGCAACACGGTTC
antisense ATTTGCGGCCGCTCAAGACTCGTGGTGACCAAAGC
pET-hrnr-3 sense ACTGAGATCTGGGTACCGACGACGACGACAAGAGTCAGCATGGGTCTGGCT
antisense ATTTGCGGCCGCTCACAAACCGGACCCATGTCGG
pET-hrnr-4 sense ACTGAGATCTGGGTACCGACGACGACGACAAGTCAGGACAGTCATCAACCTTTG
antisense ATTTGCGGCCGCTCACTGATAAAAGTAGCACCTCTGC
fraction (CSF) from the cytoplasmic insoluble fraction and cell debris was performed by
centrifugation at 15000×g for 30 min at 4◦C. The CSF was filtered (0.45 -pore-size filter;
Schleicher & Schuell GmbH) and the clarified supernatant was used for purification of
the polyhistidine-tagged protein with ProtinorNi prepared columns (Macherey-Nagel).
The fusion proteins were eluted with 1×Elution buffer (50 mM NaH2PO4, 300 mM NaCl,
250 mM imidazole, pH 8.0). The eluate pH was adjusted to 3.0 to 4.0 with 2% (v/v)
trifluoroacetic acid (TFA) and the resultedmixturewas purified by centrifugation at 8000×g
for 3 min. The clarified supernatant was subjected to preparative wide-pore C8 RP-HPLC
(RP8) with a column (SP250/10 Nucleosil 300-7 C8; Macherey-Nagel) that was previously
equilibratedwith 0.1% (v/v) TFA inHPLC-gradewater containing 10% acetonitrile. Fusion
proteins were elutedwith a gradient of increasing concentrations of acetonitrile containing
0.1% (v/v) TFA (flow rate, 3 ml/min). Fractions containing uv(215 nm)-absorbing material
were collected, lyophilized and analyzed by ESI-QTOF-mass spectrometry.
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2.10.3 Digestion and purification of the recombinant protein
The His-tagged fusion proteins purified from HPLC-RP8 were cleaved from their His-tag
with enterokinase EKMax according to the manufacturer’s suggestion (Invitrogen). The
digestion mixture contained 1 unit of EKMax per 250 µg of the fusion protein in a volume
of 500 µl and was dialyzed for 3 h (for hornerin peptides) or 16 h (for LEKTI-2 and lekti3)
at 37◦C. The dialyzed sample was centrifuged at 8000×g for 3 min at 4◦C. The separation
of the target peptide and His-tag from the fusion protein was achieved by a reverse-
phase high-performance liquid chromatography (RP-HPLC). Briefly, the supernatant was
collected and injectedonto a Jupiter-5µ-C4-300AHPLCcolumn (Phenomenex) equilibrated
with 0.1% TFA in water. Peptides were eluted with a gradient of increasing concentrations
of acetonitrile containing 0.1% (v/v) TFA (flow rate, 0.5 ml/min) (see figure legends for
details of the gradients used). Fractions of each peak were collected. The concentrations of
proteins present in HPLC fractions were estimated by ultraviolet absorbance integration
at 215 nm using ubiquitin (Sigma) for calibration.
2.10.4 Protein analysis
Proteins were separated by 10% NuPAGErNovexr Bis-Tris gel electrophoresis with MES
SDS buffer (Invitrogen). Proteins in Bis-Tris gels were stained with AgNO3 (Sigma) (Blum
et al., 1987) or Coomassie blue R-250 (Sigma). The SeeBluerPlus2 Pre-stained Standard
marker (Invitrogen) was used as a molecular mass marker (49, 38, 28, 17, 14, 6 and 3 kDa).
The polypeptide purity and molecular masses were assessed with ESI tandem MS on a
Q-TOF2 (Micromass, Manchester, U.K.) mass spectrometer.
2.11 Generation of goat antibodies
A total of 1.0 mg of protein mixture including His-tagged fusion protein and purified pep-
tide was conjugated by the glutaraldehyde method (Avrameas and Ternynck, 1969; Briand
et al., 1985) to maleimide-activated keyhole limpet hemocyanin (KLH) (protein-KLH 1 : 1,
wt/wt) and subsequently mixedwith 1.0mg of His-tagged protein for use as immunogens.
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Immunization of a goat was carried out three times at 2-week intervals. Thirteen days
after the final immunization, blood from each goat was collected and incubated at 37◦C
for 1 h to enhance clot formation and then incubated at 4◦C overnight to encourage clot
retraction. The serum was separated from the clot and stored at −70◦C until required.
2.12 Immunoblot analysis
The proteins separated by RP-HPLC were blotted to a nitrocellulose membrane (0.2− pore
size; Bio-Rad) with amounts of antigen and antiserum dilutions as indicated in Fig. 3.29
and Fig. 3.30. After blotting, the membrane was saturated at room temperature for 1 h
with PBS/M [1×PBS containing 5% (wt/vol) freeze-dried low-fat milk] and then washed
three times with PBS/T [1×PBS containing 0.05% (vol/vol) Tween]. The membrane was
incubated at room temperature for 1 h with a polyclonal antiserum diluted 1 : 1000 in
PBS/T/M (1×PBS containing 0.05% Tween and 5% freeze-dried low-fat milk). After three
washes with PBS/T, the membrane was incubated at room temperature for 1 h with goat
anti-rabbit immunoglobulin G (heavy plus light chains)-horseradish peroxidase conjugate
(Bio-Rad) diluted 1 : 30000 in PBS/T/M. Themembrane was washed three times with PBS/T
and twice with PBS. The substrate (SuperSignal West Dura extended duration substrate;
Pierce) was deposited for 5 min onto themembrane. The chemiluminescence was detected
by a CD-camera (Diana, Raytest).
2.13 Mass spectrometry
Electrospray-ionization mass spectrometry analyses were done in the positive ionization
modewith a quadrupole orthogonal accelerating time-of-flight mass spectrometer (QTOF-
II hybrid mass spectrometer; Micromass).
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2.14 Enzymatic Assays
For analysis of self-digestion, aliquots containing 20 µg of HRNR3 from RP4-HPLC were
lyophilized and dilutedwith 100 mM ammonium bicarbonate, pH 8.9. The solutions were
incubated at 37◦C for 0 h, 6 h and 16 h, respectively and subject to mass spectrometry.
2.15 Antimicrobial activity
The antimicrobial activities of of hrnr-2, hrnr-3, hrnr-4 and LEKTI-2 were assayed against
the Gram-positive bacteria Staphylococcus aureus ATCC 6538 and Enterococcus faecalis
ATCC 29212, the Gram-negative Escherichia coli ATCC 11303 and Pseudomonas aeruginosa
ATCC 10145, and the yeast Candida albicans ATCC 24433.
To measure the microbicidal activity, the purified peptide was estimated with a mi-
crodilution assay system (Steinberg and Lehrer, 1997). Test organisms were incubated for
3 h at 37◦C with purified LEKTI-2 or hornerin fragments (freshly lyophilized from HPLC
purifications and stored as a pool in 10 mM sodium phosphate buffer at −80◦C) in 10 mM
sodium phosphate buffer, pH 7.4, containing 1% (v/v) trypticase soy broth (TSB). The an-
tibiotic activity was analyzed by plating of serial dilutions of the incubation mixtures and
determination of the number of CFU the next day. The limit of detection (1 colony per
plate) was equal to 1×102 CFU/ml.
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Results
In our previous work, two putative new antimicrobial peptides were isolated and purified
from pooled stratum corneum extracts of healthy person’s heel callus, S100 fused-type
antimicrobial peptide (SFT-AMP) and kazal-type antimicrobial peptide (KT-AMP). Their
N-terminal amino acid sequences were determined by the Edman degradation method,
which are shown as following: SFT-AMP (SQHGSGSGHSSGYGQHGSR) and KT-AMP
(TKQMVDCQHYKKLPPGTTRFCHHMYYPIIG).
3.1 The human clustered S100 fused-type protein (SFTP) gene
family
3.1.1 Characterization of the full-length human hornerin cDNA
To identify the cDNA sequence and the corresponding gene of the new antimicrobial
peptide SFT-AMP, the N-terminal 19-amino-acid sequence of the natural peptide SFT-
AMP was used as a query to blast against the human EST database and genome data by
the tBLASTn algorithm on the NCBI server. This search led to a 100%-matched genomic
locus located on the genomic contig NT 029289 on chromosome 1q21.3. To generate
a partial cDNA clone for this fragment, PCR amplification was performed using reverse-
transcribedRNA fromhuman foreskin-derived keratinocytes and specific oligonucleotides
derived from the DNA sequence. Based on the resulted cDNA sequence from cloning
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and sequencing of the PCR-amplified product, we designed specific oligonucleotides and
performed 3’/5’ RACE. However we failed to get any band from RACE.
To determine the full-length cDNA sequence for human SFT-AMP, comprehensive
bioinformatic analysis was then used to help predict the gene structure for SFT-AMP. The
SFT-AMP gene is located between trichohyalin (THH) and profilaggrin (PFLG), which is a
locus for the epidermal differentiation complex (EDC) region, a highly conserved syn-
teny to mouse chromosome 3F2 (http://www.ensembl.org/Homo sapiens/syntenyview)
(Fig. 4.2). According to the gene order on mouse EDC, the human SFT-AMP seemed
to be a putative synteny to the mouse hornerin (GenBank Accession No. NM 133698).
The amino-acid sequence of the mouse hornerin was then used as a query to blast against
human EST database and genome data by the tBLASTn algorithm to look for the can-
didate DNA sequence on the Ensemble Genome Browser. This method allowed us to
find two exons encoding the potential human hornerin, one of which contained the locus
encoding SFT-AMP peptide and many GC-rich repeats. Based on the predicted two-exon
DNA sequence, a serious specific oligonucleotides were designed to to be used for 3’/5’
RACE and PCR walking. The cDNA sequence was completed by combining the over-
lapping sequences from each PCR product and submitted to GenBank with an accession
No. AY396741 (Fig. 5.3). The full-length cDNA (9632 bp) contained an ORF consisting of
8553 bp, from nucleotides 80 to 8632, and a polyadenylation signal (AATAAA) situated 14
nucleotides 5’ of the poly(A) tail. The deduced protein chain consisted of 2850 amino acids,
containing a S100 domain (residues 4–46), a EF-hand domain (residues 51–80), a spacer
sequence (residues 82–246), six tandem repeats A crosslinking with five tandem repeats
B (Fig. 3.1). The mature peptide SFT-AMP is represented by the repeat unit A6 (residues
2591–2684, Fig. 3.1A).
3.1.2 Characterization of three novel SFTP members cDNAs
To identify candidate novel S100 fused-type protein (SFTP) members genes within the
human genome, we used the tBLASTn algorithm and the 80-amino-acid sequences of the
two conserved EF-hand domains of all the known SFTP members, such as human THH,
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Figure 3.1: Schematic structure of human hornerin protein. A, the schematic structure of hornerin
protein. The hornerin proprotein contains a S100 domain, an EF-hand domain, a spacer sequence
andmultiple tandemrepeats; B, the full-length amino-acid sequence of hornerin and the localization
of conserved motifs and repeats (repeat A marked red while repeat B green). The mature peptide
SFT-AMP isolated was underlined red.
PFLG, hornerin (HRNR), C1orf10 and mouse repetin (RPTN), as a query against human
genomic data (Build 33, available on April 30, 2003) to search for DNA loci with potential
EF-hand domains. This search led to the identification of a contig NT 032962 in the human
chromosome 1q21.3 (Fig. 4.2). A total of seven putative homologous loci were clustered
at this contig. Among them, three correspond respectively to known genes, THH, PFLG
and C1orf10, one to HRNR while the other three are putative novel gene loci which were
designated later as trichohyalin like 1 (THHL1), RPTN, and ifapsoriasin (IFPS). The exon
3 of the novel gene was predicted on the DNA sequence of the contig NT 032962. By
using the PCR-walking strategy and the SMART RACE procedure as described above,
corresponding THHL1, RPTN, and IFPS overlapping cDNA clones were obtained and
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sequenced.
THHL1. In both the 5’ and 3’ experiment, a single extended product was detected
by using the specific primers based on the related S100/EF-hand DNA sequence. The
full-length cDNA (3603 bp) of THHL1 was completed with the two overlapping cDNA
sequences from sequencing results of RACE products, which contained an ORF consisting
of 2715 bp and a poly(A) signal (AATAAA) situated 12 nucleotides 5’ of the poly(A) tail
(GenBank accession No. AY456639). The deduced protein chain consisted of 904 amino
acids containing a S100 domain (residues 4–46), a EF-hand domain (residues 52–80) and
an AAA-ATPase domain (residues 170–526).
RPTN and IFPS. In the 5’ experiment, a single extended product was detected by
using the specific primers of each gene. The PCR-walking strategy was used to confirm
the middle cDNA sequence while the 3’ SMART RACE was used to determine the 3’-
end cDNA sequences. All the partial cDNA clones were obtained and sequenced. The
full-length cDNAwas completed with the overlapping cDNA sequences from sequencing
results of both PCR-walking and RACE products. The full-length RPTN cDNA (3569
bp) contained an ORF consisting of 2355 bp and a poly(A) signal (AATAAA) situated 15
nucleotides 5’ of the poly(A) tail (GenBank accession No. AY396742). The deduced RPTN
protein chain consisted of 784 amino acids containing a S100 domain (residues 4–46), a
EF-hand domain (residues 51–80), a spacer sequence (residues 81–268), thirteen tandem
repeats with 24 amino-acid residues each and the C-terminal sequence (Fig. 3.2A and
B). The full-length IFPS cDNA (9117 bp) contained an ORF consisting of 7176 bp and a
poly(A) signal (AATAAA) situated 9 nucleotides 5’ of the poly(A) tail (GenBank accession
No. AY827490). The deduced IFPS protein chain consisted of 2391 amino acids containing
a S100 domain (residues 4–46), a EF-hand domain (residues 51–80), two spacer sequences
(residues 81–268) and two kinds of tandem repeats (Fig. 3.3).
3.1.3 Genomic structure of human SFTP genes
The genomic structure of human SFTP geneswas analyzed by using the BLAT algorithm to
compare each mRNA sequence with the human genome sequence assembled in May 2004
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Figure 3.2: Schematic structure of human repetin protein. A, The schematic structure of repetin
protein. The repetin proprotein contains a S100 domain, an EF-hand domain, a spacer sequence
and 13 tandem repeats; B, the full-length amino-acid sequence of repetin and the localization of
conserved motifs and repeats.
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TTGRRGSGHSEYSDSEGPSGVSHT-HSG--HTHGQAGSHYPESGSSVHERHGTTHGQTADTTRHGHSGHGQSTQRGSR
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Figure 3.3: Schematic structure of human ifapsoriasin protein. A, the schematic structure of
ifapsoriasin protein. The ifapsoriasin proprotein contains a S100 domain, an EF-hand domain, two
spacer sequences and two kinds of tandem repeats (repeats A and B); B, the full-length amino-acid
sequence of ifapsoriasin and the localization of conserved motifs and repeats.
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in the UCSC server. All introns were flanked by the consensus donor and acceptor splice
sites. The putative TATA box was found on about 25 bp before the upstream genomic
sequence of the transcription start site (TSS) site of each gene. All the SFTP genes consisted
of three exons, exon 1 being untranslated and exon 2 containing the ATG start codon and
encoding the S100 domain; exon 3 was the largest and contained the high G+C content of
the underlying DNA and the TAA/TGA/TAG stop codon (Fig. 3.4).
C1orf10                       48 1967 151 1152 1838
Hornerin   54 864 163 1626 9992 
A
55 937 158 791 3362 
Ifapsoriasin                56                  7015                      160                     1099                      7911   
 THHL1                       54                    830                      158                      619                       2719 
 Trichohyalin               54                  1279                      169                      864                       5559 
Profilaggrin               54                  9611                      159                       570                    12584 
 Gene                   Exon I (bp)      Intron I (bp)      Exon II (bp)      Intron II (bp)      Exon III  (bp) B
Repetin
Figure 3.4: Comparison of genomic structure of the human SFTP genes. A, Schematic
representation of the genomic and exon/intron consensus organization for the human
SFTP genes. Boxes represent exons, green-colored regions indicate the coding sequence,
and intervening lines denote introns. B, Exon/intron sizes and boundaries.
3.1.4 Tissue distribution of human SFTP expression
To determine tissue distribution of each human SFTP gene expression, we performed RT-
PCR and real-time PCR analyses (Fig. 3.5 and Table. 3.1). To prevent the possibility of
contamination from genomic DNA, RT samples were treated with DNase I (to destroy
any remaining genomic DNA in our sample) before PCR amplification. To further ex-
clude the possibility that our positive signal may result from genomic DNA amplification,
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intron-spanning primer pairs specific to each gene were designed according to the cDNA
sequences of exons 1 and 2. From all the 23 tissues analyzed, SFTPs were not only strongly
expressed in keratinocytes but also in other tissues. IFPSmRNAwas restricted to skin and
small intestine and THHmRNAwas restricted only to skin. THHL1 also showed a narrow
expression profile and its mRNA was detected in nasal epithelia, tongue and neutrophils
and weakly expressed in skin. Other SFTP members (HRNR, PFLG, RPTN and C1orf10)
showed a broad expression profile. More interestingly,HRNRmRNAwas also detected in
bone marrow and neutrophils.
Figure 3.5: RT-PCR analysis of human SFTP expression. RNA was isolated from the indi-
cated human tissues and cells. TheRNAwas treatedwith reverse transcriptase followedby
PCR amplification with a SFTP-specific primer pair or a GAPDH-specific primer pair and
the analysis of amplification products by agarose gel electrophoresis. The housekeeping
gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was employed as a loading
control. BEC, bronchial epithelial cells; TEC, trachea epithelial cells; Kera-ck, untreated
keratinocytes; Kera-PA, keratinocytes treated with Pseudomonas aeruginosa; Kera-PMA,
keratinocytes treated with phorbol-myristate-acetate (PMA).
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Table 3.1: Realtime RT-PCR analysis of human SFTP transcripts. A transcript copy number
determined by real-time PCR using cDNA as a template. Results represent the average
of two independent cDNA samples. In all cases, copy numbers were normalized against
GAPDH transcripts and shown by 1000 times. BEC, bronchial epithelial cells; TEC, trachea
epithelial cells.
Tissue THHL1 THH RPTN HRNR PFLG IFPS C1orf10
Spleen 0 0 0 0 0 0 0.278
Thymus 0 0 1.32 0 5.54 0 0
Inner epithelia 0 0 0 0 0 0 0
Small intestine 0 0 0.0325 0 0.110 0.0581 0
Bone marrow 0 0 0 0.0803 0 0 0
Neutrophils 20.3 0 0 0.0887 0 0 0
Tonsil 0 0 176 0 1.26 0 47.9
Tongue 990 0 139 0.0575 0.633 0 114
Stomach 0 0 0 0.067 0 0 1.93
BEC 6.66 0 157 0.0627 3.27 0 29.8
Larynx 0 0 0 0 0 0 0.0792
Colon 0 0 0 0.546 0 0 0
Nasal epithelia 72200 0 2.16 0.0791 0 0 3.44
Adenoid 0 0 14.0 0 0 0 0.478
Polyp 0 0 0 0 0 0 44.4
A549K 0 0 0 0 0.0091 0 0
TEC 0 0 14.3 0 0 0 0
Salivary grand 0 0 0 0 0 0 4.45
Kidney 0 0 0 0 0 0 0
Uterus 0 0 53.1 16.2 1.44 0 457
skin 3.09 37.2 59.3 0 32070 1672 5.12
Keratinocytes 0.329 2.27 7.81 43.1 441 6.27 10.7
3.1.5 Expression of human SFTP genes in skin disease tissues
To analyze expression of SFTPs in skin cancer tissues, realtimeRT-PCRwasperformed. The
expression levels of all SFTP familymembers were examinedwith paired tissue specimens
(Table 3.2). No significant difference in SFTPs levels between skin precancerous lesions
and paired normal tissues were detected, although the relative amounts of SFTPs levels
differed among cases.
The expression levels of PFLG and IFPS were found to be decreased in SCC cases but
were increased in BCC cases. The most significant difference was found in three cases. In
case BCC-63, the C1orf10 expression level was increased 987 times in BCC lesion compared
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to the normal tissue. In case SCC-86, the hornerin expression level was increased 190 times
in involved lesion than the paired normal tissue. In case SCC-63, the repetin expression
level was increased 78 times in involved lesion than the paired normal tissue.
Table 3.2: Expression analysis of human SFTPs in tumor skin samples. The transcript copy
numberwas determined by real-time PCRusing cDNAas a template. Always paired tissue
specimens were analyzed (a, uninvolved tissue; b, involved tissue). In all cases, mRNA
copy numbers were indicated as the absolute value per 1 ng total RNA. NS, normal skin;
BCC, Basal Cell Carcinoma; SCC, Squamous cell carcinoma; PL, Precancerous Lesions.
Tissue THHL1 THH RPTN HRNR PFLG IFPS C1orf10
Normal skin 0.04 33.3 1.38 0.26 81.3 6.8 1.45
PL-28a 11.2 170 26.6 0.11 5428 528 105
PL-28b 4.5 34.1 19.2 0.44 1882 171 38.0
PL-91a 1.49 79.8 19.7 0.35 4867 219 53.6
PL-91b 2.45 59.5 26.7 0.53 9718 323 271
PL-111a 3.5 47.4 10.5 0.21 4248 168 63.1
PL-111b 3.12 44.4 4.89 0.19 845 71.5 10.5
SCC-63a 1.43 14.3 29.3 0.3 9212 559 278
SCC-63b 12.86 105 383 3.31 34600 1415 4225
SCC-73a 4.67 77.5 22.4 1.97 4840 442 202
SCC-73b 0.75 39.1 25.7 0.73 19570 711 237
SCC-86a 10.6 194 5.13 0.23 17610 541 244
SCC-86b 1.43 34.1 73.4 43.4 48670 875 191
SCC-109a 0.38 24.5 10.7 0.42 4155 550 180
SCC-109b 0.76 1.21 9.31 0.49 214 19.0 5.97
SCC-130a 2.16 10.4 11.2 0.28 8709 263 93
SCC-130b 1.52 0.82 3.69 0.3 540 63.1 17.9
BCC-1a 0.11 13.4 12.0 0.91 21300 486 87.7
BCC-1b 0.14 3.44 110 11.9 6634 167 532
BCC-14a 21.83 410 5.13 0.22 7480 187 111
BCC-14b 1.37 56.7 13.4 0.97 2506 119 109900
BCC-43a 4.72 158 6.37 0.26 6844 455 77.5
BCC-43b 0.22 0 7.82 1.42 848 76.1 9072
BCC-56a 0.52 29 3.6 0.17 9829 169 82.7
BCC-56b 0.12 0 11.8 0.19 1885 99.4 2679
BCC-95a 4.91 93.4 9.11 0.26 4115 133 88
BCC-95b 3.30 56.3 25.4 1.21 14860 647 424
To obtain more clues, expression of SFTPs in other skin diseases tissues were also
examined (Fig. 3.6). The relative amounts of SFTPs (including PFLG, IFPS, C1orf10, RPTN
and THH) levels were decreased in the involved skin tissue with inflammation, psoriasis
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or DTC (acute allergic contact dermatitis) when compared with the paired normal tissues.
The highest significant difference was found in IFPS levels in the case PS-3 (Fig. 3.6).
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Figure 3.6: Expression of human SFTPs in skin disease tissues. SFTP mRNA was assayed in the
lesional (a) and nonlesional (b) skin of four patients with inflammation, psoriasis vulgaris or acute
allergic contact dermatitis and the normal skin of four healthy controls by real-time quantitative
RT-PCR. A transcript copy number was determined by real-time PCR using cDNA as a template.
In all cases, copy numbers were normalized against the copy number of the GAPDH gene. NS,
normal skin; IS, inflamed skin; DTC, acute allergic contact dermatitis; PS, psoriasis lesions.
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3.1.6 Comparative analysis of human SFTPmRNA-expression in proliferating
and differentiating human keratinocytes
We compared the expression of SFTP family members in human foreskin-derived ker-
atinocytes and examined whether or not this expression is altered by addition of retinoic
acid (RA) or extracellular calcium. As shown in Fig. 3.7, 1.7 mM calcium increased
the mRNA levels of all SFTP family members in keratinocytes after 2-day incubation,
while 10−7 M RA depressed completely their mRNA levels during eight days incubation.
Calcium-induced expression of SFTP genes was associated with profound morphological
changes, consistent with the onset of the differentiation program. Calcium significantly
increased mRNA levels of PFLG, RPTN, IFPS, C1orf10 and THHL1 after 2 days and these
increases were maintained over the course of six days exposure. The expression of THH
and HRNR was also induced slightly after 2 days, although their relative mRNA levels
were found to be very low. These results suggest that all SFTP genes are late differentiation
markers of human keratinocytes.
To determine whether the SFTP promoter activity is related to upstream MAP kinase
pathways, cells were treated with selective pharmacological inhibitors of ERK, JNK and
p38. As shown in Fig. 3.8, either p38 inhibitors SB202190 and SB203580 or the MEK
inhibitor PD98059 had no effect on SFTPs expression whereas the JNK inhibitor SP600125
upregulated SFTPs expression. Compared with calcium-dependent expression, the JNK
inhibitor produced higher induction of RPTN, PD98059 or C1orf10 promoter activity than
that of PFLG or HRNR.
Given that SFTP promoter activity is strongly regulated by MAPK pathways, we spec-
ulated whether the calcium-mediated induction was dependent on this signalling. To
address this issue, cells were treated with different combinations of selective pharmaco-
logical inhibitors of ERK, JNK and p38. As shown in Fig. 3.9, these drugs each affected the
ability of calcium to induce RPTN/IFPS promoter activity. The combination of PD98059
and SP202190 markedly inhibited calcium-mediated induction, whereas the combination
of SP600125 and SP202190 or the three combination of SP600125, PD98059 and SP202190
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Figure 3.7: Human SFTP-expression in human foreskin-derived keratinocytes in response to
calcium or retinoic acid. Second passage human keratinocytes were treated with 1.7 mM calcium
or 10−7 MRA. The cells were harvested at day 2, day 4 and day 7 respectively. The mRNA for SFTP
genes were analyzed by real-time quantitative RT-PCR. A transcript copy number was determined
by real-time PCR using cDNA as a template. In all cases, copy numbers were normalized against
the copy number of the GAPDH gene and expressed as copies per 1000 GAPDH copies.
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Figure 3.8: The ability to induce SFTP promoter activity is dependent on crosstalking of MAPKs.
Second passage primary human keratinocytes were treated with 1.7 mM calcium, 10 mM MEK
inhibitor PD98059, 10 mM JNK inhibitor SP600125, 5 mMp38 inhibitor SB202190 or SB203580. The
cells were harvested at day 2, day 4, day 6 and day 8 respectively. respectively. ThemRNA for SFTP
genes were analyzed by real-time quantitative RT-PCR. A transcript copy number was determined
by real-time PCR using cDNA as a template. In all cases, copy numbers were normalized against
the copy number of the GAPDH gene and expressed as copies per 1000 GAPDH copies.
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produced low induction of RPTN, or IFPS promoter activity with a peak at day 8 after
treatment. Conversely, the three combination of SP600125, PD98059 and SP202474 (a p38
inactive analog) resulted in the lowest effect on the calcium-mediated induction. The
RPTN/IFPS expression reached a peak at day 2 after treatment, then gradually decreased,
but remained at high levels even at day 8. These results indicate that calcium-mediated
changes in RPTN and IFPS expression are dependent on crosstalking of ERK, p38/MAP
kinase and JNK. Both ERK and p38 positively regulate SFTPs expression in response to
calcium whereas JNK inhibits SFTPs expression.
3.2 Identification of four novel human kazal-type serine protease
inhibitor-like cDNAs (SPINKs)
3.2.1 Characterization of the full-length human LEKTI-2 cDNA
To identify the human LEKTI-2 cDNA sequence, we first used the N-terminal 30-amino-
acid sequence of the natural peptide KT-AMP as a query and the tBLASTn algorithm
against human genome data to look for the candidate DNA sequence on the NCBI server.
This search led to a best-matched fragment within one putative exon, located on the
genomic contig NT 029289, which corresponds to amino acid residues 5-30 of KT-AMP
(Fig. 3.10A). To generate a partial cDNA clone for this fragment, we performed PCR
amplification using reverse-transcribed RNA from human foreskin-derived keratinocytes
and specific oligonucleotides derived from the predicted cDNA sequence. Based on the
resulted cDNA sequence from cloning and sequencing the PCR-amplified product, we
designed specific oligonucleotides and performed 3’/5’ RACE. This method allowed us to
amplify two fragments containing the 5’ and 3’ end of the full-length cDNA, respectively.
The cDNA sequence was completed by combining the overlapping sequences from each
PCR product (Fig. 3.10B) . The full-length cDNA (453 bp) contained an ORF consisting of
258 bp, from nucleotides 56 to 313, and a polyadenylation signal (AATAAA) situated 14
nucleotides 5’ of the poly(A) tail. The deduced protein chain consisted of 86 amino acids.
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Figure 3.9: The ability of calcium to induce SFTP promoter activity is dependent on
crosstalking of MAPKs. Second passage human keratinocytes were treated with different
combinations of 10 mM MEK inhibitor PD98059, 10 mM JNK inhibitor SP600125, 5 mM
p38 inhibitor SB202190 and 5 mM p38 inactive analog SB202474 for 2h and maintained in
EpiLife medium containing 1.7 mM calcium. The cells were harvested 2 d, 4 d, 6 d and
8 d respectively. The mRNA for RPTN and IFPS were analyzed by real-time quantitative
RT-PCR. A transcript copy number was determined by real-time PCR using cDNA as a
template. In all cases, copy numbers were normalized against the copy number of the
GAPDH gene and expressed as copies per 1000 GAPDH copies.
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The 16 residues from the firstMet represents a leader sequence containing a signal peptide.
A short hydrophobic region located between amino acid 3 and 25 that was predicted by
the SignalP application encodes the transmembrane signal anchor. This putative signal
anchor is followed by a typical so-called kazal domain that spanned the residues 26-61,
which corresponds to the native KT-AMP peptide, as predicted by the SMART program
(Fig. 3.10C).With highhomology to domains 2 and 15 of amulti ’Lympho-Epithelial-Kazal-
type-Inhibitor’ (LEKTI), the matured protein was designated as LEKTI-2 and the gene
was designated as SPINK9 (serine protease inhibitor, kazal type 9) (GenBank accession
No. AY396740).
3.2.2 Characterization of SPINK9 homologous cDNAs
To identify candidate SPINK9 homologs genes within human genome, chromosome 5q32,
we used the tBLASTn algorithm and the 61-amino-acid sequence of LEKTI-2 kazal domain
as a query against human genomic data (Build 33, available on April 30, 2003) to search
for DNA loci with potential kazal domain. This search led to the identification of a contig
NT 029289 in the human chromosome 5q32. A total of 8 putative homologous loci were
clustered at 5q32. Among them, three correspond respectively to known genes, SPINK1
(GenBank accession No. NM 003122), SPINK5 (GenBank accession No. NM 205841)
and ECG2 (GenBank accession No. NM 032566), one to SPINK9 while the other four are
putative novel gene loci which were designated here as SPINK6, SPINK7, SPINK8 and
SPINK10. By using RT-PCR and the SMART RACE procedure as described above, corre-
sponding SPINK6, SPINK7, SPINK8 and SPINK10 full-length cDNA clones were obtained
from keratinocytes and sequenced. During the course of this work, nucleotide and protein
sequence databases (mainly GenBank and SwissProt) were periodically searched. The
mRNA or predicted sequences for SPINK6, SPINK7 and SPINK8 have recently appeared
in GenBank database though detailed cloning and characterization of these mRNA and
protein sequences has not been reported.
SPINK6. In the 5’ experiment, two extended products were detected with different
transcription start site (TSS) but sharing the same first exon. In the 3’ experiment, a single
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A.
B.
C.
Figure 3.10: Nucleotide and amino acid sequences of human SPINK9. A, the best-matched
fragment located on the genomic contig NT 029289 was found by the tBLASTn program. B, the
full-length nucleotide sequence of human SPINK9 cDNA (453 bp) was verified by direct cDNA
cloning and sequencing and aligned with the predicted open reading frame amino acid sequence.
The underlined red nucleotides indicated the canonical poly(A) addition signal. C, schematic
representation of the predicted domain architecture of human LEKTI-2. The locations of the signal
peptide (marked red) and kazal domain (arrow) are indicated.
extension product was detected which contained a polyadenylation signal (AATAAA)
situated 214 nucleotides 5’ of the poly(A) tail. The full-length cDNA (946 bp for the
longer transcript; 883 bp for the shorter one) contained an ORF consisting of 243 bp
(Fig. 3.11A). Compared with the newly identified SPINK6/MGC21394 (GenBank accession
No. NM 205841) (Strausberg et al., 2002), all the three SPINK6 transcripts contain the
same ORF though showing both 5’ and 3’-end extensional transcription in keratinocytes.
The deduced protein chain consisted of 80 amino acids with a leader sequence containing a
signal peptide (residues 1–24) while the residues 7-26 represent a transmembrane domain.
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The last 54 residues include the kazal domain (Fig. 3.11).
         TSS1
      1 gtgaatcatccctataatgtagtgaaactttagaaagaagagccgggaggatgtattggt
             TSS2
     61 tgttaggaaaatgtaggctaccagtagaaaatgacattctctattaataagatctgaggt
    121 gcgacacacataattgtcccaatttttaagattgatggggagcatgaagcatttttttaa
    181 tgtgttggcaggccccattaaatgcataaactgcataggactcatgtggtctgaatgtat
    241 tttagggctttctgggaattgtcttgacagagaacctcagctggacaaagcagccttgat
    301 ctgagtgagctaactgacacaatgaaactgtcaggcatgtttctgctcctctctctggct
                             M  K  L  S  G  M  F  L  L  L  S  L  A  
    361 cttttctgctttttaacaggtgtcttcagtcagggaggacaggttgactgtggtgagttc
        L  F  C  F  L  T  G  V  F  S  Q  G  G  Q  V  D  C  G  E  F  
    421 caggacaccaaggtctactgcactcgggaatctaacccacactgtggctctgatggccag
        Q  D  T  K  V  Y  C  T  R  E  S  N  P  H  C  G  S  D  G  Q  
    481 acatatggcaataaatgtgccttctgtaaggccatagtgaaaagtggtggaaagattagc
        T  Y  G  N  K  C  A  F  C  K  A  I  V  K  S  G  G  K  I  S  
    541 ctaaagcatcctggaaaatgctgagttaaagccaatgtttcttggtgacttgccagcttt
        L  K  H  P  G  K  C  *
    601 tgcagccttcttttctcacttctgcttatacttttgctggtggattcctttaattcataa
    661 agacatacctactctgcctgggtcttgaggagttcaatgtatgtctatttctcttgattc
    721 acttgtcaataaagtacattctgcaaaagcattgactgtgttcttactttgagatcaaga
    781 aaatatatacatacaacagagaataattgaactgggataaacttggatcaagaaacctat
    841 tttcctgatctaagttaaccatccagtcattgtgagatcataggaaaatcccttcctttc
    901 tcttattcttagaatctccatgtttataatgaaggattttgacaaca 946
Figure 3.11: Nucleotide and amino acid sequences of human SPINK6. The full-length
nucleotide sequence of human SPINK6 cDNAwas alignedwith the predicted open reading
frame amino acid sequence. The underlined nucleotides indicated the canonical poly(A)
addition signal. The two transcript variants of SPINK6 are indicated. TSS1, transcription
start site 1; TSS2, transcription start site 2.
SPINK8. In the 5’ experiment, three extended products were detected. In the 3’
experiment, a single extension product was detected which contained a polyadenylation
signal (AATAAA) situated 20 nucleotides 5’ of the poly(A) tail. Three PCR fragments were
obtained after a long-distance PCR with a pair of specific primers derived from 5’ and 3’
end. The full-length cDNA of SPINK8-v1(1022 bp) contained an ORF consisting of 285
bp, from nucleotides 532 to 816, which is exactly the same as that of the newly predicted
SPINK5L2 mRNA sequence (GenBank accession No. XM 376433). The deduced protein
chain consisted of 94 amino acids with a leader sequence containing a signal peptide
(residues 1–24) while the residues 4-26 are a transmembrane domain. The residues 47–93
are a kazal domain. The other twovariants (1171 bp for SPINK8-v2; 1088 bp for SPINK8-v3)
didn’t encode any kazal domain.
SPINK7. In both the 5’ and 3’ experiment, a single extended product was detected.
The full-length cDNA (522 bp), designated here SPINK7-v2 (SPINK7 splicing variant
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2), contained an ORF consisting of 214 bp and a poly(A) signal (AATAAA) situated 18
nucleotides 5’ of the poly(A) tail (Fig. 3.12A). The deduced protein chain consisted of
71 amino acids. Compared with the newly identified human SPINK5L2 partial mRNA
sequence (GenBank accession No. NM 001001325; designated here SPINK7-v1) (Puente
and Lopez-Otin 2004), SPINK7-v2 contains the same kazal domain (residues 13-71) as v1
(Fig. 3.12B–D). In contrast, SPINK7-v1 possessed a leader sequence containing a signal
peptide (residues 1–22) and a transmembrane domain (residues 7–26), as is typical for a
SPINK protein, while SPINK7-v2 contains no signal peptide or transmembrane domain.
1 gagatttatttgagtaataactccagtcctactgcttggctagctctgcattaataagac
61 gcttttggctgggctcagtggctcATGcctgtaatcccagcactttgggaggcgaaggtg
M P  V  I  P  A  L  W  E  A  K  V 
121 aaatgtccatatgagaaagtaaacttgagctggtacaatggaacggtcaacccctgccct
K  C  P  Y  E  K  V  N  L  S  W  Y  N  G  T  V  N  P  C  P 
181 ggcttatatcaacccatctgcggcaccaattttataacctatgataatccctgcattctg
G  L  Y  Q  P  I  C  G  T  N  F  I  T  Y  D  N  P  C  I  L 
241 tgtgttgagagcttgaaatctcatggaagaatcaggttttaccatgatggaaaatgttag
C  V  E  S  L  K  S  H  G  R  I  R  F  Y  H  D  G  K  C  * 
301 ctgagtggacttgaatgtggaagatatcttcttttttttttcctccatgtctccaatctc
361 cctcttgcgctttttacatctccttgcatttgttcttcatgacaaagagctatcactact
421 gagcttgtagcagattgttcaaagttccttccatggacctctcccctcactgactgattg
481 ccttccatagtctccctaataaatacacttttatgaaagtc 521    
A.
C.
B. CLUSTAL W (1.82) multiple sequence alignment
SPINK7-v2                                                        MPVIPALWEA  10     
SPINK7-v1       MAKSFPVFSLLSFILIHLVLSSVSGPRHWWPPRGII  35
SPINK7-v2                          KVKCPYEKVNLSWYNGTVNPCPGL 34 
SPINK7-v1                            KVKCPYEKVNLSWYNGTVNPCPGL 60 
SPINK7-v2   YQPICGTNFITYDNPCILCVESLKSHGRIRFYHDGKC 71 
SPINK7-v1   YQPICGTNFITYDNPCILCVESLKSHGRIRFYHDGKC 97
D.
Figure 3.12: Nucleotide and amino acid sequences of human SPINK7. A, The full-length
nucleotide sequence of human SPINK7-v1 cDNA was aligned with the predicted open
reading frame amino acid sequence. The underlined nucleotides indicated the canonical
poly(A) addition signal; B, Alignment of the full-length protein sequences of the both
SPINK7 variants; C, SPINK7-v1 domain architectures. The location of kazal domain
(arrow) is indicated; D, SPINK7-v2 domain architectures. The locations of the signal
peptide (marked red) and kazal domain (arrow) are indicated.
SPINK10. In the 3’ experiment, a single extension product was successfully detected
but in the 5’ experiment no product was obtained. The deduced amino acid sequence
of the 3’ RACE PCR product then was used as a query to BLASTp and tBLASTn against
public protein and EST databases on theNCBI server. This search led to a best-matched ho-
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mologous protein, the double-headed protease inhibitor (DHPI) from dog submandibular
gland (Swissprot accession No. P01002), and two EST sequences from bovine gut (EMBL
accession Nos. CK946321 and CK946653) which can be assembled as a putative full-length
cDNA sequence encoding the possible bovine DHPI. The predicted bovine DHPI amino
acid sequence was used as a query to tBLASTn against human genome data to look for the
5’ end cDNA sequence of human DHPI. After being defined by computer analysis of exon-
intron boundary, the full-length cDNA (1172 bp), designated here SPINK10, was generated
which contained an ORF consisting of 405 bp and a poly(A) signal (ATTAAA)(Fig. 3.13A).
The deduced protein chain consisted of 134 amino acids with a leader sequence contain-
ing a signal peptide (residues 1–21) and two kazal domains (residues 29–83 and 86–134)
(Fig. 3.13B).
3.2.3 Genomic structure of human SPINK9 and its homologs genes
The genomic structure of human novel SPINKs genes was analysed by using the BLAT
algorithm to compare each mRNA sequence with the human genome sequence assembled
in May 2004 in the UCSC server (http://genome.ucsc.edu/cgi-bin/hgBlat). The mRNA
sequence of SPINK9 was aligned perfectly to an unique genome region on the SPINK9
gene. These alignment data clearly indicate that each unique mRNA segment represents
an individual exon. Thus, according to the specific location of each mRNA segment and
the distance between each segment on the gene, the exon/intron structure of this gene can
be predicted. All introns were flanked by the consensus donor and acceptor splice sites.
The SPINK9 gene consists of four exons, exon 4 being the largest and exon 2 being the
smallest; exon 1 contains the ATG start codon, and exon 4 contain the TAA stop codon
(Fig. 3.14).
The SPINK10 gene consists of six exons, exon 6 being the largest and exon 2 being the
smallest; exon 1 contains the ATG start codon, and exon 6 contains the TGA stop codon
(Fig. 3.15).
The SPINK6 gene consists of four exons, exon 4 being the largest and exon 2 being the
smallest; exon 1 contains the ATG start codon, and exon 4 contain the TGA stop codon.
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      1 tcttctctctctggactccttggctcagagcagcatatctccatcattggcattcaccat
     61 cactATGaagggcttcactgcttttgccatccttggtctagcagtcactgcttgggctac
            M  K  G  F  T  A  F  A  I  L  G  L  A  V  T  A  W  A  T  
    121 ctcgccatatgcaaaagggacaaaggtgaactgttccagatacattaaaggcttaaagac
         S  P  Y  A  K  G  T  K  V  N  C  S  R  Y  I  K  G  L  K  T  
    181 tgcatgcccaagagactggagaccaatatgtggcacagatcagaaaacttacagtaatga 
         A  C  P  R  D  W  R  P  I  C  G  T  D  Q  K  T  Y  S  N  E
    241 atgcatgttttgcatgcaaaaccaggaagtagatcaagaatttcaactcagaaaacttca
         C  M  F  C  M  Q  N  Q  E  V  D  Q  E  F  Q  L  R  K  L  H  
    301 tgaaggtaaatgtcagattcagtgtaccaggtattctgaggcatgtaccatggactacac
         E  G  K  C  Q  I  Q  C  T  R  Y  S  E  A  C  T  M  D  Y  T 
    361 acttcactgtggatctgatggaaatgtatattccaacagatgtaccttttgcaataccgt 
         L  H  C  G  S  D  G  N  V  Y  S  N  R  C  T  F  C  N  T  V 
    421 tgtgaagagccaaggtgcaatttggttgaaaaattatggattgtgctgaatctccctgat
         V  K  S  Q  G  A  I  W  L  K  N  Y  G  L  C  * 
    481 gcttaaggatatcaagtctcctttggcagattccacttagataaccagtttgtcttggac
    541 ggctgaggaggcaagcaataatctggtacaaacatggatttgagtcttcaacaaagtatt
    601 ctcagcaaggaactgactatcagtcctatctgtggatgtgattcttctcttaaggagaat
    661 atctatggtcattttcctaagctaaaaatcatatagaaagattttctctatttctataca
    721 aattgggaactagatattatacacacaatggtgagaagagaatatgcttatatcatgttt
    781 aaaagactcaattgttttaagtaaacatgagtcagaggatggatctgtccattggtctca
    841 tattatctttggcacactaatgaagtgaaaaatttagatttggagaaagtgagaatccaa
    901 aatactatacactaatcagaacagaccagtcataacgtatattttaggtgtcatcattta
    961 aagaggactcagtcacgtatgggcacatgcaaaaaaggcattatgttgaagggagagaga
   1021 cattaaaaacaagatctgattgattaaatgttgaagtcactaaaaggcctcaggaaaata
   1081 tgatggaggtgggaatgatgagggtatattcaaaaccatcctgagagagaaactccagaa
   1141 ttttctcatctagcatgccatagaaagcaccc 1172   
 
 
A
B
Figure 3.13: Nucleotide and amino acid sequences of human SPINK10. A, The predicted full-
length nucleotide sequence of human SPINK10 cDNAwas alignedwith the predicted open reading
frame amino acid sequence. The 3’-end sequence fromnucleotides 318 to 1172was verified bydirect
cDNA cloning and sequencing while the 5’ end sequence was predicted by bioinformatic analysis.
The underlined nucleotides indicated the canonical poly(A) addition signal. B, SPINK10 domain
architectures. The locations of the signal peptide (marked red) and kazal domains (arrow) are
indicated.
This structure also demonstrates the different transcription start sites of exon 1 to produce
the long and short form mRNAs. All the mRNAs (SPINK6-v1, -v2 and -v3) are produced
by utilizing all exons (thus the same protein) except that the SPINK6-v3mRNA is obtained
by utilizing shortened 5’ and 3’ UTR (Fig. 3.16).
The SPINK8 gene consists of eight exons including five constant exons (c1–5) and
three variable exons (v1–3), c1 being the largest and v3 being the smallest; c3 contains
the ATG start codon, and c5 contain5 the TGA stop codon (Fig. 3.17). This structure also
demonstrates the alternative splicing of exon v1–3 to produce the three form mRNAs
(SPINK8-v1, -v2 and -v3). The SPINK8-v1 mRNA is produced by utilizing exons c1–5 and
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Exon1 Exon2 Exon3 Exon4
intron3intron2intron1
SPINK9/LEKTI2
SPINK9 gene
A
Exon cDNA position 
(bp)
Exon size 
(bp)
Intron size 
(bp)
1 1-110 110 753
2 111-142 32 2024
3 143-270 128 1061
3' splice acceptor 
(intron/exon)
5' splice donor 
(exon/intron)
B
SPINK9
4 271-453 183
tttcttccag/GTATAGAATG
gttttttcag/GTTGACTGCA
ctctccacag/GAAAACTGAC 
ACCATGTTCA/gtgagtatct
GAAACAGATG/gtcagtacac 
CTAAAGTTAA/gtaagtatta
Figure 3.14: Genomic structure of the human SPINK9. A, Schematic representation of the genomic
and exon/intron organization for the human SPINK9. Boxes represent exons, green-colored regions
indicate the coding sequence, and intervening lines denote introns. B, Exon/intron sizes and
boundaries. The splice acceptor and donor sequences are shown in upper and lower case letters,
respectively.
Exon cDNA position 
(bp)
Exon size 
(bp)
Intron size 
(bp)
1 1-131 131 606
2 132-145 14 526
3 146-270 125 1579
3' splice acceptor 
(intron/exon)
5' splice donor 
(exon/intron)
B
SPINK10
4 271-313 43
ggtgatcaaa/CAAAAGGGAC 
ccaactatag/GTGAACTGTT
tctcttccag/AGATCAAGAA 
TCGCCATATG/gcaagtcagg
AGGGACAAAG/gtgagtgcaa 
ACCAGGAAGT/gttatactca
5 314-423 110 458
6 424-1172 749
tctgatggag/CAGATTCAGT
tttcttgtag/GAAGAGCCAA 
ATACCGTTGT/gtaagtgctg
1247AGGTAAATGT/gtaagtatat
Exon1 Exon2 Exon3
SPINK10
SPINK10 gene
A Exon4 Exon5 Exon6
Figure 3.15: Genomic structure of the human SPINK10. A, Schematic representation of the
genomic and exon/intron organization for the human SPINK10. Boxes represent exons,
brown-colored regions indicate the coding sequence, and intervening lines denote introns.
B, Exon/intron sizes and boundaries. The splice acceptor and donor sequences are shown
in upper and lower case letters, respectively.
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Exon1 Exon2 Exon3 Exon4
intron3intron2intron1
SPINK6-v1
SPINK6 gene
A
Exon cDNA position 
(bp)
Exon size 
(bp)
Intron size 
(bp)
1 1-379 379 2881
2 380-402 23 7851
3 403-518 116 879
3' splice acceptor 
(intron/exon)
5' splice donor 
(exon/intron)
B
SPINK6-v1
4 519-947 429
tttctttcag/GTGTCTTCAG 
actttggtag/GTTGACTGTG
ttttttgtag/GAAAAGTGGT 
TTTTTAACAG/gtaagttttt
GGGAGGACAG/gtcagtgcct 
AGGCCATAGT/gtaagtatta
1  64-379 315 2881
2 380-402 23 7851
3 403-518 116 879
SPINK6-v2
4 519-947 429
tttctttcag/GTGTCTTCAG 
actttggtag/GTTGACTGTG
ttttttgtag/GAAAAGTGGT 
TTTTTAACAG/gtaagttttt
GGGAGGACAG/gtcagtgcct 
AGGCCATAGT/gtaagtatta
1 65-379 314 2881
2 380-402 23 7851
3 403-518 116 879
SPINK6-v3
4 519-750 232
tttctttcag/GTGTCTTCAG 
actttggtag/GTTGACTGTG
ttttttgtag/GAAAAGTGGT 
TTTTTAACAG/gtaagttttt
GGGAGGACAG/gtcagtgcct 
AGGCCATAGT/gtaagtatta
SPINK6-v2
SPINK6-v3
Figure 3.16: Genomic structure of the human SPINK6. A, Schematic representation of
the genomic and exon/intron organization for the three splice variants. Boxes represent
exons, green-colored regions indicate the coding sequence, and intervening lines denote
introns. B, Exon/intron sizes and boundaries for the mRNA isoforms (SPINK6-v1, -v2 and
-v3). The splice acceptor and donor sequences are shown in upper and lower case letters,
respectively.
v3, whereas the SPINK8-v2 mRNA is obtained by utilizing all but exon v2 and that the
SPINK8-v3 mRNA is obtained by utilizing all but exon v1. More interestingly, the exon v3
for SPINK8-v3 adopts a different splice acceptor.
The SPINK7 gene consists of at least four exons according to the newly isolated
SPINK5L2 mRNA partial sequence (SPINK7-v1) from human skin (5’ and 3’ UTR se-
quences remain unknown); exon 1 contains the ATG start codon, and exon 4 contains the
TAG stop codon (Fig. 3.18). However, to our surprise, the SPINK7-v2 mRNA is produced
by utilizing exons 3 and 4 on the gene locus 5q32 while its 5’-end mRNA leader sequence
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V1 602-750 149 gactat tcag/GTGGAACAAT GCTGGAA AAG/gtaaggaaat 3434
C1 1-328 328 311C2 329-498 170 1151
C3 499-601 103 1794SPINK8-v3
V3 665-705 41
ggtcactcag/CTATGCGATG 
atgttcacag/GCCTTATCAA
tctttattag/CAGGAATTTT
CTGGAATGTG/gtaggtcatt
CCTCATCCAG/gtaaccactc 
GCTTTCT CAG/gtgagtaacc
C4 706-833 128 3768
C5 834-1088 255
gtatttgcag/CCCCGATGTA
ttctctttag/GGAATTTCAT 
TTGAACAGAG/gtaagttcag
7719GTGGCCTAAG/gtaaatttaa
V2 602-664 63 tcttccttag/AAACTCCAGG CTCCAGAATT/gtaagataat 3344
C1 C2 C3 V1
SPINK8-v1
SPINK8 gene
A
SPINK8-v2
SPINK8-v3
V3V2 C4 C5
Figure 3.17: Genomic structure of the human SPINK8. A, Schematic representation of
the genomic and exon/intron organization for the three splice variants. Boxes represent
exons, green-colored regions indicate the coding sequence, and intervening lines denote
introns. B, Exon/intron sizes and boundaries for the mRNA isoforms (SPINK8-v1, -v2 and
-v3). The splice acceptor and donor sequences are shown in upper and lower case letters,
respectively.
(117 nucleotides) is obtained by utilizing a foreign exon from the reversed complement
strand at human chromosome 7q11.23. The foreign exon contains a retroviral sequence
(nucleotides 1–66) and an Alu sequence (nucleotides 67–117).
To understand the chimeric structure of SPINK7-v2 mRNA, PCR analysis was per-
formed by using genomic DNAs as templates (Fig. 3.19). Four pairs of specific primers
were designed with the retrieved genomic DNA sequences at 5q32 on the NCBI server.
All the PCR products were sequenced. The results showed that both the commercial ge-
nomic DNA (CG-DNA) and the fresh-prepared genomic DNA (KG-DNA) isolated from
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foreskin-derived keratinocytes possess a common 3973 bp region upstream of the gene
exon 3. By using the fourth pair of primers to generate an expected product ”D”, a related
PCR product was found in CG-DNA but not in KG-DNA. This suggests that there could
be a genomic breakage point, a big-fragment integration or interruption within the related
region in KG-DNA.
Exon1 Exon2 Exon3 Exon4
intron3intron2intron1
SPINK7-v1 
(SPINK5L2)
SPINK7 gene 
(5q32)
A
Exon cDNA position 
(bp)
Exon size 
(bp)
Intron size 
(bp)
1  1-67 67 1130
2  68-111 44 3260
3 112-248 137 982
3' splice acceptor 
(intron/exon)
5' splice donor 
(exon/intron)
B
SPINK7-v1
4 249-294 46
tat tctctag/TTTCAGGCCC 
tcaatttcag/GTGAAATGTC
cttcctttag/GAAATCTCAT 
TTATCTTCTG/gtgagtaatt
AATTATTAAG/gtaatgttcc
TTGAGAGCTT/gtgagtacta
v1   1-117 117
3 118-254 137 982
SPINK7-v2
4 255-521 267
tcaatttcag/GTGAAATGTC
cttcctttag/GAAATCTCAT 
TTGAGAGCTT/gtgagtacta
SPINK7-v2
chromosom
7q11.23
GGAGGCGAAG/gtgggtggat
Figure 3.18: Genomic structure of the human SPINK7. A, Schematic representation of the
genomic and exon/intron organization for the two mRNA-splice variants. Boxes represent
exons, green-colored regions indicate the coding sequence, brown-colored regions indicate
the untranslated sequence and intervening lines denote introns; B, Exon/intron sizes and
boundaries for the mRNA isoforms (SPINK7-v1 and -v2). The splice acceptor and donor
sequences are shown in upper and lower case letters, respectively.
3.2.4 Expression analysis of the human SPINKs
To determine the expression pattern of the newly identified human SPINKs genes, RT-PCR
analyses were performed on twenty-three adult tissue samples (Fig. 3.20). From all the 23
tissues analyzed, only foreskin-derived keratinocytes presented a clearly detectable signal
for all SPINK mRNAs tested, while no detectable levels for SPINK6, SPINK7-v2 mRNA
or SPINK9 were seen in normal skin. SPINK7-v2 mRNA was restricted to bone marrow.
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2 kb
1.5 kb
1.0 kb
0.6 kb
1.2 kb
1M M2 2 2 21 1 1
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Exon3
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Figure 3.19: GenomicPCRanalysis of thehumanSPINK7gene. Twokindsof genomicDNA
were used: 1, a commercial human genomic DNA from Promega; 2, the fresh-prepared
genomic DNA isolated from foreskin-derived keratinocytes. The PCR amplification was
performed with a specific primer pair (upper panel) and the analysis of amplification
products was done by agarose gel electrophoresis (lower panel). Lanes A–D each corre-
sponds to the expected PCR products on the upper panel. The arrow-marked bands were
confirmed by sequencing.
Moderate expression of SPINK8-v1 was detected in lung and low expression in skin and
colon. SPINK9mRNAwas highly expressed in thymus but also low in tonsil, adenoid and
brachial epithelial cells (BEC). SPINK6 mRNA was expressed in thymus, small intestine,
neutrophils, BEC, larynx, pharynx, colon and polyp.
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Figure 3.20: RT-PCR analysis of human SPINKs mRNA-expression. RNA was isolated
fromhuman tissues and cells as indicated. The RNAwas treatedwith reverse transcriptase
followed byPCRamplificationwith a SPINK-specific primer pair (lower andmiddle panel)
or a GAPDH-specific primer pair (upper panel) and the analysis of amplification products
was performedby agarose gel electrophoresis. GAPDHwas employed as a loading control.
BEC, bronchial epithelial cells; TEC, tracheal epithelial cells; Kera-ck, untreated primary
keratinocytes.
To analyze the expression of SPINKs in skin cancer tissues, we examined the expression
of the four SPINK genes byRT-PCRwith paired tissue specimens (Fig. 3.21). SPINK6 exhib-
ited a complex expression profile among different cases. SPINK7-v2 mRNA was detected
only in the involved tissue of one patient with precancerous lesions. High expression of
SPINK9was found in two cases, namely PL-91 and SCC-63. In contrast to only SPINK8-v1
mRNA transcript detected in the colon, skin and keratinocytes (Fig. 3.21), a complex alter-
native splicing pattern was found in tumor skin. A total of three different SPINK8mRNA
transcripts (SPINK8-v1, -v2 and -v3) were isolated and confirmed by sequencing (Fig. 3.17).
3.3 Functional analysis of the human hornerin and LEKTI-2
3.3.1 Purification and Characterization of recombinant hornerin fragments
The PCR fragment encoding protein fragments consisting of 50, 98, 72 or 124 amino acid
residues of hornerin was subcloned into an expression vector (pET32a) to yield pET32a-
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Spink8
Spink9
 a   b    a    b    a   b    a    b    a    b    a    b     a    b    a     b     a     b    a    b    a    b     a    b
28 91 111 63 73 86 109 130  1 43 56 95
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Figure 3.21: RT-PCR analysis of human SPINKs expression in tumor skin. Paired tissue
specimens were analyzed (a, uninvolved tissue; b, involved tissue). NS, normal skin; BCC,
basal cell carcinoma; SCC, squamous cell carcinoma; PL, precancerous lesions.
HRNR-1, pET32a-HRNR-2, pET32a-HRNR-3 and pET32a-HRNR-4, respectively. The ex-
pression of recombinant fusion proteins in E. coli BL21trxB(DE3)pLysS was induced by
the addition of isopropyl-β-D-thiogalactopyranoside (IPTG) as described in Materials and
Methods. The soluble and insoluble cytoplasmic fractions, separated from induced E. coli
cells and analyzed by Tricine-SDS-PAGE, revealed that the fusion protein accumulated
essentially as soluble material in the cytoplasmic fraction of E. coli (data not shown). Sub-
sequently, the fusion protein was purified by ProtinorNi prepared columns kits and then
by RP8-HPLC (Fig. 3.22 A, Fig. 3.23 A, Fig. 3.24 A and Fig. 3.25 A). Mass analysis indicated
post-translational removal of the initial methionine (Fig. 3.22 C, Fig. 3.23 C, Fig. 3.24 C and
Fig. 3.25 C).
The (Asp)4-Lys sequence located upstream of the insert protein sequence is the target
of enterokinase (EK). This enzymatic cleavage was used to recover the related protein. The
(His)6-HRNR-(1–4) fusion proteins were subjected to 3-hour cleavage process. The EK-
treated fractions were purified further by RP4-HPLC (Fig. 3.22 B, Fig. 3.23 B, Fig. 3.24 B and
Fig. 3.25 B) and were subjected to mass analysis (Fig. 3.23 D, Fig. 3.24 D and Fig. 3.25 D).
Mass spectrometry confirmed the EK proteolytic products of three fusion proteins corre-
sponding to the polypeptidesHRNR2,HRNR3andHRNR4. However, within the resulting
RP4-HPLC peaks of EK-treated His-HRNR1, there was no exact mass that corresponded
to the polypeptide HRNR1.
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A. B.
C.
20000 20500 21000 21500 22000 22500 23000 23500 24000 24500
mass0
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21399
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21813
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22768
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241962410223062 23882
23428
24587
24655 24944
Predicted average mass:
His-HRNR1: 22869 Da
His-HRNR1(-Met): 22737 Da
D. Protein sequence:
NDPDTVDIILQSLDRDHNKKVDFTEYLLMIFKLVQARNKIIGKDYCQVSG
Predicted average mass: 5811 Da
Figure 3.22: Purification and characterization of the His-tagged fusion protein His-HRNR1. A,
the Ni-column-bound His-tagged fusion proteins of E. coli extracts were separated by RP8-HPLC,
and the fraction containing the highest peak was collected. The red arrow indicates the highest
peak; B, the enterokinase-treated fraction was purified by RP4-HPLC, and the resulting peaks were
collected and subjected to mass analysis; C, ESI-MS spectrum of the purified His-HRNR1 revealed
an exact mass of 22737 Da. The red arrow indicates the mass corresponding to the predicted mass;
D, the amino acid sequence and predicted mass of HRNR1.
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Figure 3.23: Purification and characterization of the hornerin fragment HRNR2. A, the Ni-
column-bound His-tagged fusion proteins of E. coli extracts were separated by RP8-HPLC, and the
fraction containing the highest peak was collected. The red arrow indicated the highest peak; B, the
enterokinase-treated fraction was purified by RP4-HPLC, and the resulting peaks were collected
and subjected to mass analysis. The red arrow indicates the peak with an ESI-MS spectrum shown
in Fig. D; C, ESI-MS spectrum of the purified His-HRNR2 revealed an exact mass of 26335 Da.
The red arrow indicates the mass corresponding to the predicted mass of His-HRNR2; D, ESI-MS
spectrum of the purified recombinant HRNR2 revealed an exact mass of 9409 Da. The red arrow
indicates the mass corresponding to the predicted mass of HRNR2. The amino acid sequence of
HRNR2 is shown in the box.
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Figure 3.24: Purification and characterization of the hornerin fragment HRNR3. A, the Ni-
column-bound His-tagged fusion proteins of E. coli extracts were separated by RP8-HPLC, and the
fraction containing the highest peak was collected. The red arrow indicated the highest peak; B, the
enterokinase-treated fraction was purified by RP4-HPLC, and the resulting peaks were collected
and subjected to mass analysis. The red arrow indicates the peak with an ESI-MS spectrum shown
in Fig. D; C, ESI-MS spectrum of the purified His-HRNR2 revealed an exact mass of 23985 Da.
The red arrow indicates the mass corresponding to the predicted mass. D, ESI-MS spectrum of the
purified recombinant HRNR3 revealed an exact mass of 7059 Da. The red arrow indicates the mass
corresponding to the predicted mass. The amino acid sequences of HRNR3 fragments are shown
in the box.
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Figure 3.25: Purification and characterization of the hornerin fragment HRNR4. A, the Ni-
column-bound His-tagged fusion proteins of E. coli extracts were separated by RP8-HPLC, and the
fraction containing the highest peak was collected. The red arrow indicates the highest peak; B, the
enterokinase-treated fraction was purified by RP4-HPLC, and the resulting peaks were collected
and subjected to mass analysis. The red arrow indicates the peak with an ESI-MS spectrum shown
in Fig. D; C, ESI-MS spectrum of the purified His-HRNR2 revealed an exact mass of 29529 Da.
The red arrow indicates the mass corresponding to the predicted mass. D, ESI-MS spectrum of
the purified recombinant HRNR4 revealed an exact mass of 12603 Da. The red arrow indicates the
mass corresponding to the predicted mass. The amino acid sequence of HRNR4 is shown in the
box.
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The RP4-HPLC pattern confirmed the purity of the polypeptides. However, mass
spectrometry returned multiple polypeptide mass peaks for HRNR2, HRNR3 and
HRNR4. These results confirmed that HRNR2, HRNR3 and HRNR4 were purified in the
flowthrough fraction. Moreover, the apparent fractions of HRNR2, HRNR3 and HRNR4
were not recognized in SDS-Page analysis by Coomassie staining (Fig. 3.26) or silver stain-
ing (data not shown).
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M C MCB BAA
HRNR-2HRNR-3
Figure 3.26: SDS-PAGE analyses of fusion proteins and cleaved mature polypeptides. Two
hornerin-fragments-fusion proteins (HRNR2 and HRNR3) were analyzed. A, total proteins before
induction; B, total proteins after 3h inductionof 1mMIPTG;C, theRP4-HPLCpurifiedpolypeptides
HRNR2 and HRNR3.
3.3.2 Purification and Characterization of recombinant LEKTI-2
The PCR fragment encoding the protein consisting of 61 amino acid residues of LEKTI-2
was subcloned into an expression vector (pET32a) to yield pET32a-LEKTI-2. The ex-
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pression purification of recombinant fusion protein in E. coli BL21trxB(DE3)pLysS was
performed as described above. Mass analysis indicated post-translational removal of
the initial Met and the complete formation of three disulfide bridges of LEKTI-2 was con-
firmed (Fig. 3.27A andC). The (His)6-LEKTI-2 fusion proteinwas subjected to an overnight
cleavage process in the presence of enterokinase. The enterokinase-treated fractions were
purified further by RP4-HPLC and were subjected to mass analysis (Fig. 3.27 B and D).
Mass spectrometry revealed a single polypeptide mass of 7058 Da for LEKTI-2, in full
agreement with the expected theoretical molecular mass (7064 Da) minus six hydrogens
due to forming of three disulfide bonds (6 Da).
3.3.3 Analyses of protease activity of HRNR3
The complex ESI-MS spectra of hornerin fragments suggested an autoproteolytic process.
To prove this hypothesis, the purified recombinant hornerin fragment HRNR3 was tested
in 100 mM NH4HCO3 solution at 37◦C for 16 h. ESI-MS analyses revealed multiple
polypeptide mass peaks, three of which were clearly mapped to two c-terminal sequences
(4262 Da and 5207 Da) and one N-terminal sequence (6394 Da) of HRNR3, which were
cleaved after the arginine residue (Fig. 3.28).
3.3.4 Analyses of antimicrobial activity of human hornerin fragments and
LEKTI-2
Antimicrobial activities of of HRNR2, HRNR3, HRNR4 and LEKTI-2 were assayed against
the Gram-positive bacteria Staphylococcus aureus ATCC 6538 and Enterococcus faecalis
ATCC 29212, the Gram-negative Escherichia coli ATCC 11303 and Pseudomonas aeruginosa
ATCC 10145, and the yeast Candida albicans ATCC 24433 (Table 3.3), using the microdilu-
tion assay system, as described in the Materials and Methods section. In the antimicrobial
assay system used, recombinant LEKTI-2 exerted antifungal activity against C. albicans
ATCC 24433 with a LD 90 at 50 µg/ml, while recombinant hornerin fragments displayed
activity, with degree of variation between the target microorganisms. HRNR2 andHRNR4
exhibited weak activity against the Gram-negative bacteria tested, but showed higher
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Figure 3.27: Purification and characterization of recombinant LEKTI-2. A, the Ni-column-bound
His-tagged fusion proteins of E. coli extracts were separated by RP8-HPLC, and the fraction con-
taining the highest peak was indicated by a red arrow and collected; B, the enterokinase-treated
fraction was purified by RP4-HPLC, and the resulting peaks were collected and subjected to mass
analysis. The red arrow indicates the peak with an ESI-MS spectrum shown in Fig. D; C, ESI-MS
spectrum of the purified His-LEKTI-2 revealed an exact mass of 23984 Da. The red arrow indicates
the mass corresponding to the predicted mass. D, ESI-MS spectrum of the purified recombinant
LEKTI-2 revealed an exact mass of 7058 Da. The red arrow indicates the mass corresponding to the
predicted mass. The amino acid sequence of LEKTI-2 was inserted.
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Figure 3.28: ESI-MS spectra ofHRNR3 in 10mMNH4HCO3 buffer. The red arrow indicates
the mass corresponding to the predicted mass. The amino acid sequences of HRNR3
fragments are shown in the box
activity against the yeast C.albicans. HRNR3 was almost 10 times more active against
E.coli and P.aeruginosa than HRNR2 and HRNR4. The Gram-positive bacteria S. aureus
ATCC 6538 and E. faecalis ATCC 29212 were resistant to the peptides.
Table 3.3: MBCs and LD90s of hornerin peptides and LEKTI-2. MBC, minimal bactericidal
concentration (indicates 99.9% killing).
Organisms value HRNR2 HRNR3 HRNR4 LEKTI-2
E. coli ATCC 11303 MBC (µg/ml) >100 >100 >100 >100
LD90 (µg/ml) >100 12.5 >100 >100
P. aeruginosa ATCC 10145 MBC (µg/ml) >100 50 >100 >100
LD90 (µg/ml) 100 6.25 >100 >100
S. aureus ATCC 6538 MBC (µg/ml) >100 >100 >100 >100
LD90 (µg/ml) >100 >100 >100 >100
E. faecalis ATCC 29212 MBC (µg/ml) >100 >100 >100 >100
LD90 (µg/ml) >100 >100 >100 >100
C. albicans ATCC 24433 MBC (µg/ml) >100 25 >100 >100
LD90 (µg/ml) 12.5 3.125 100 50
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3.3.5 Generation of polyclonal goat antisera against hornerin fragments and
LEKTI-2
Recombinant proteins (hornerin fragments HRNR2, HRNR3 and HRNR4 and LEKTI-
2) were mixed with their corresponding His-tagged fusion protein and conjugated to
maleimide-activated keyhole limpet hemocyanin (KLH). The conjugate was used in the
immunization of goats. Thirteen days after the final immunization, blood from each goat
was collected and the serum was separated from the clot.
The activity of the polyclonal goat antiserum was first tested by dot-blot assays using
various purified antigens purified from RP-HPLC. 1 : 1000 and 1 : 3000 dilutions of each
antiserum were tested with antigen amounts ranging from 0.1 ng to 1000 ng. As shown
in Fig. 3.29, the anti-LEKTI-2 antiserum reacted with the LEKTI-2 fraction tested at both
dilutions; however, the 1 : 3000 dilution was two dilution steps less sensitive. Though the
anti-LEKTI-2 antiserum showed cross-reactivity with the HRNR2 fraction, a faint reaction
was seen only with high amounts (≥ 30 ng) of antigen and was clearly distinguishable
from reactions that were still observed with 0.1 ng of LEKTI-2 antigen. Likewise, anti-
HRNR2 antiserumgave a similar reaction patternwith theHRNR2 fraction and the LEKTI-
2 fraction, but less than 1 ng of antigen was not detected at both dilutions.
The activity of the antisera against HRNR4 (Fig. 3.30) was tested using a dot blot assay
with a variety of RP-HPLC fractions containing natural hornerin fragments, recombinant
HRNR4 or recombinant LEKTI-2 at a serum dilution of 1 : 1000 or 1 : 3000. The sera gave
a positive reaction with natural hornerin fragments from fraction 8 to 15 and recombinant
HRNR4 at both dilutions; however, the 1 : 3000 dilution was only one dilution step less
sensitive. The sera did not react with recombinant LEKTI-2.
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Figure 3.29: Titrations of goat antisera in dot-blot assays. Amounts of 0.1 to 1000 ng of
LEKTI-2 (A) or HRNR-2 (B) were spotted onto nitrocellulose membranes and reacted with
polyclonal goat antiserum against LEKTI-2 or HRNR2 at the indicated dilutions.
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Figure 3.30: Titrations of goat anti-HRNR4 antisera in a dot-blot assay. Amounts of 0.1
to 1000 ng of recombinant HRNR4 (A) or LEKTI-2 (B) and 1 µl of RP-HPLC fractions
containing natural hornerin fragments (C) were spotted onto nitrocellulose membranes
and reacted with polyclonal goat antiserum against HRNR4 at the indicated dilutions.
Chapter 4
Discussion
An initial clue about the function of the hornerin and LEKTI-2 genes was obtained by
the previous work in our group, which revealed that the stratum corneum of healthy
skin contained marked antimicrobial activity that was related to the presence of several
antibacterial molecules. The data presented in this thesis elucidated their gene structures,
determined their full-length cDNA sequences and characterized part of their protein func-
tions. Remarkably, these genes appear to be constitutively present and belong to two
multigene families, the SFTP gene family clustered in chromosome 1q21.3 and the SPINK
gene family clustered in chromosome 5q32. Therefore, also included here is a complete
dissection of both gene clusters and comparative analysis of their gene expression and
their putative gene evolution.
It is widely accepted that the prevalence of gene families in vertebrates has important
functional consequences, such as the frequent occurrence of unexpectedly weak mutant
phenotypes due to redundancies between paralogues. An exhaustive characterization of
the composition of the studiedmultigene families is a prerequisite for effective clarification
of the gene function. This is currently made possible by the availability of an increasing
number of sequenced genomes in vertebrates.
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4.1 The human clustered S100 fused-type protein (SFTP) gene
family
Using the public available in-silico tools, we found that the human SFTP gene family
consistes of seven members, including the previously characterized profilaggrin (PFLG)
(Fleckman et al., 1985) , trichohyalin (THH) (Lee et al., 1993), and c1orf10 (Xu et al., 2000)
and four so far uncharacterized genes, THHL1, repetin (RPTN), hornerin (HRNR) and ifap-
soriasin (IFPS). Based on the retrieved DNA sequences, the 5’ and 3’ cDNA sequences of
the four novel members were determined by RACE RT-PCR. Unfortunately, except for
THHL1, the long-distance PCR failed to isolate the full-length cDNA sequences of the re-
lated genes. Sequence analysis indicated that each of the novel three genes (RPTN, HRNR
and IFPS) containsmanyGC-rich repeatswithin the exon 3,whichwas a techniqueproblem
for all PCR-based methods and cDNA isolation techniques because high GC-containing
templates generate frequently local secondary structure, leading to inefficient PCR (Fil-
ichkin and Gelvin, 1992). Then an alternative short-distance RT-PCRwalking strategy was
adopted to determine the full sequences. This technical approach taken would seem to be
the only reliable way to identify the exact sequence of SFTPmRNAs, or similarly repetitive
protein structures.
To clarify the grouping of family members, BLAT was used to identify SFTPs genomic
sequences (Kent, 2002). AligningmRNAandgenomicDNAsequence revealed intron/exon
structures. In addition, chromosomal locations of SFTP family members were also iden-
tified. Interestingly, the intron/exon structure of the SFTP genes is strictly conserved in
the human chromosome 1q21.3: a small untranslated exon 1 followed by a small exon 2
containing the translation start site ATG and coding for the S100 domain and a large exon 3
coding the EF-hand domain and the rest part of the big proprotein (Fig. 3.4). They were
closely clustered in a head-to-tail mode without any gene gap unrelated. Intron/exon
structures can thus be used as a criterion for the identification of SFTP homologs in distant
species.
To identify their primary protein structures, the amino acid sequences of theN-terminal
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two EF-hand domains of the human SFTP proteins were compared with that of all the
synteny in mouse and rat (Fig. 4.1). All SFTPs matched perfectly the consensus pattern
for two domains: S-100/ICaBP type calcium binding protein signature (Kligman and Hilt,
1988) and EF-hand calcium-binding domain (PROSITE PDOC00018). In contrast, most
parts of these proteins showed low-homology relationship (data not shown).
S100 domain EF-hand domain
Figure 4.1: Multiple alignment of the conserved domains of the SFTP proteins. The amino-
acid sequences of the partner S100 and EF-hand domains have been truncated to improve
the alignment. The conserved amino acids are shaded in red. Roman numerals at the top
correspond to residue numbers. The domain pattern is indicated at the bottom. Hs, homo
sapiens; Mm,Mus musculus; Rn, Rattus norvegicus.
To identify the Mus musculus SFTPs ortholog to human SFTPs, tBLASTN searches
via the BLAT algorithm were carried out with the full-length sequences of the human
SFTPs proteins against the mouse and rat genome, respectively. The data obtained were
contrasted with gene predictions from the mouse Genome Initiative. For all the genes
(THHL1, THH, RPTN, HRNR, PFLG, IFPS and C1orf10) a genomic structure of coding
exons was found to be totally conserved, including the gene order and the positions of the
exon-intron boundaries. The mouse SFTPs orthologs mapped to chromosome region 3F2
(Fig. 4.2).
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Figure 4.2: Comparative analysis of a cluster of human SFTPs at 1q21.3 with the corre-
sponding region of mouse genome. The order and orientation of genes are indicated by
black/red arrowheads. Orthology is indicated by connecting lines.
For a closer inspection of the relationship of all the protein sequences, their N-
terminal 100-amino-acid sequences were aligned using DiAlign on the Genomatix server
(http://www.genomatix.de/cgi-bin/dialign/dialign.pl) to the currently known S100A-type
proteins selected from the NCBI protein database. The phylogenetic tree was generated
from the sequence alignment and shown as an unrooted cladogram (Fig. 4.3). According
to this tree, each human SFTP genes has an extremely conserved counterpartner in chim-
panzee (Pan troglodytes), mouse and rat. The tree can be primarily subdivided into several
clades, distinguished by the sequence variability. The SFTPs protein sequences have clus-
tered together into a single clade comprising all the 28 SFTPs isoforms distributed within
the down half of the phylogenetic tree separately from all the human S100 sequences. This
Clade contains two sub-branches, one including profilaggrin, hornerin and Ifapsoriasin,
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another including repetin, C1orf10, trichohyalin and THHL1. In addition, hornerin and
Ifapsoriasin proteins have grouped together separately from the profilaggrin, whereas
THHL1 and trichohyalin have grouped together separately from repetin and C1orf10.
4.2 The human clustered kazal-type serine protease inhibitor
(SPINK) gene family
A total of three members of the SPINK gene family have been previously characterized,
which include SPINK1 (Horii et al., 1987), SPINK5 and ECG2 (Cui et al., 2003). In this study
five so far uncharacterized SPINK genes, SPINK6, SPINK7, SPINK8, SPINK9 and SPINK10,
were identified and found to be clustered within a very small region in chromosome 5q32.
The genomic structure of the SPINK gene cluster is less conserved compared to that of the
SFTP gene cluster. However, analysis from amino acid sequences revealed a high overall
sequence homology and indicated that all eight SPINKmembers have an identicalmodular
structure that was specific for kazal-type serine protease inhibitors. This included a short,
but variable, N-terminal cytoplasmic tail, the putative signal anchor, and one-to-several
C-terminal kazal domains. Except for the SPINK1, all the other SPINKs members showed
the same transcriptional direction (Fig. 4.6).
To identify their primary protein structures, the amino acid sequences of the kazal
domains of the human putative SPINKs identified at 5q32 were compared with the typ-
ical kazal type family members and SPINK5 domain 2 and 15 (Fig. 4.4). All SPINKs
matched perfectly the consensus pattern for kazal domains: C-x(7)-C-x(6)-Y-x(3)-C-x(2,3)-
C (PROSITE PDOC00254), and therefore are homologous to PSTI (PDB code: 1tgs), acrosin
inhibitor (PDB code: 2bus), ovomucoid (PDB code: 1ovo and 2ovo), and human SPINK1
(PDB code: 1cgi). Besides the consensus kazal residues, SPINKs exhibit asparagine at
position 36, a structurally important residue strongly conserved among serine protease
inhibitors (Schechter and Berger, 1968). Interestingly, the SPINK9 mature peptide is ex-
tremely basic, having a net charge of +9.13, while a seminal plasma inhibitor IIa from
Cow (Bos taurus)(PDB code:2bus) has the next larger charge at +9.02 (Strop andWuthrich,
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Clade 1
Clade 2
Figure 4.3: Unrooted cladogram of the human SFTP and S100A family and their orthologs in
chimpanzee, mouse and rat. The tree, based onN-terminal 100 amino acid residues of each protein,
shows the relationships among known S100 domains from SFTP and S100 families.
1983).
The neural network-based tool SignalP allows the discrimination of subcellular des-
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Figure 4.4: Multiple alignment of the kazal domains of the human SPINKs protein family. The
partner kazal domain sequences have been truncated to improve the alignment. The conserved
amino acids are shaded in red. The asterisk points to the conserved Asn residue. the two arrows
above the alignment mark the active residue position P1 and P1’. Roman numerals at the top
correspond to residue numbers. The disulfide pattern found in the kazal type is indicated at the
bottom. The theoretical pIs (isoelectric points) are listed on the right-hand side.
tination of newly identified proteins based on the N-terminal sequence information only
(Dyrlov Bendtsen et al., 2004). The five human SPINKs (SPINK6-v1, SPINK7-v1, SPINK8-
v1, SPINK9 and SPINK10) contained a N-terminal signal targeting sequence but not any
other signals for specific retrieval, retention, or commitment, so that they are predicted to
be transported to the cell surface. Besides the signal peptide, there was also a predicted
transmembrane (TM) helix located at the N-terminus by using the SOSUI algorithm (Mi-
taku et al., 2002). Therefore, the luminal protein of human SPINKs might be secreted
constitutively to the extracellular space and their TM domains will reside at the plasma
membrane. In contrast, SPINK7-v2 was distinguished by the absence of signal peptide or
TM, which suggests SPINK7-v2 function as a soluble protein inside the cell. As shown as
an example, Figure 4.5 showed the human SPINK9 protein was predicted to be secreted to
the extracellular space and anchored at the plasma membrane with the TM trace sequence
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(IECAKQ). The 6-residue TM anchor was cleaved further before SPINK9 became a mature
protein.
Extracellular Space
Plasma  Membrane
CS-2
CS-1
Cytoplasmic Space
Figure 4.5: Schematic representation of subcellular destination of the human SPINK9. The
schematic map was generated by the SOSUI algorithm. The subcellular destination was pre-
dicted by the TargetP program while the cleavage site of signal peptide (CS-1) was done by the
SignalP program. The second arrow with CS-2 points to the second cleavage site between the raw
and mature protein.
The SPINK inhibitors belong to a family of proteins which inhibit a number of serine
proteases (such as trypsin and elastase). To date, 7 different mammalian SPINKs have
been identified, of which 5 are found in humans. As shown above we identified 5 novel
SPINKs at 5q32.
For the Mus musculus and Rattus norvegicus SPINKs orthologs, tBLASTN searches
via the BLAT algorithm were carried out with the human SPINK kazal domains against
the mouse and rat genome respectively. The data obtained were contrasted with gene
predictions from the mouse and rat Genome Initiative. In most genes (SPINK1, SPINK3,
SPINK5, SPINK6, SPINK7, SPINK8 and ECG2) a genomic structure of coding exons is
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totally conserved, including the positions of the exon-intron boundaries. The mouse
SPINK orthologs mapped to two separate chromosome regions from SPINK3 (SPINK3
to 18C and ECG2 to 18E1). Likewise, the rat SPINK orthologs mapped to two separate
chromosome regions from SPINK1 (SPINK1 to 18p11, and ECG2 to 18q12.1) (Fig. 4.6). In
contrast, the mouse and rat genome lacked two ortholog genes for human SPINK9 and
SPINK10.
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Figure 4.6: Comparative analysis of a cluster of human SPINKs at 5q32 with the corre-
sponding region of mouse and rat genomes. The order and orientation of the genes are
indicated by black/red arrowheads. Orthology is indicated by connecting lines.
For theM. musculus and R. norvegicus additional SPINKs homolog, tBLASTN searches
were carried out with the human SPINK kazal domains against the mouse and rat genome
on the Ensemble Genome Browser. The data obtained in the mouse and rat chromosome
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18 were contrasted with gene positional identity and exon/intron conservation to human
SPINKs. We predicted seven novel SPINKs at mouse 18C–18E1 and eight at rat 18p11–
18q12.1. However, no recognizable mouse/rat ortholog to human SPINK9 or SPINK10
has been found in the corresponding syntenic region of mouse/rat chromosome. Mouse
N7 (or rat N7) is localized in the putative ortholog site to human SPINK9 but they shave
only a low homology. As the ortholog of human SPINK10 is also present in pig, cow
and dog, the gene represents a mammal-specific gene compared with rodents and a very
recent duplication event in mammals leading to the generation of a gene (double-headed
protease inhibitor) distantly related to SPINKs (Gururajan et al., 1998; Velasco et al., 1998).
For a closer inspection of the relationship of all the SPINKs protein sequences, they
were aligned using DiAlign on the Genomatix server to the current 5 kazal-type motifs
selected from the PDB database (Fig. 4.7). A single conserved domain became evident
which is a kazal domain at the C-terminus and is encoded by one exon, which suggested
that the SPINKs genes likely have been resulted from a gene duplication event.
To further explore the structural and evolutionary relationships between the newly
identified SPINKs and other members of the kazal-type family, we next performed a
computational phylogenetic tree analysis. The phylogenetic tree was generated from the
sequence alignment seen above and shown as an unrooted cladogram (Fig. 4.8). According
to this tree, most human SPINKs genes (SPINK1, SPINK2, SPINK4, SPINK5, SPINK6,
SPINK7, SPINK8, SPINK9 and ECG2) have an extremely conserved counterpartner in
mouse and rat. The tree can be primarily subdivided into four clades, distinguished by
the sequence variability within the kazal-domain. Clade 1 comprises 3 SPINKs isoforms
(SPINK5, SPINK9 and ECG2) distributed within the upper half of the phylogenetic tree.
Clade 2 comprises 2 SPINKs isoforms (SPINK7 and SPINK8) and expanded rodent N7.
Clade 3 comprises 2 SPINKs isoforms (SPINK4 and SPINK6) and 4 expanded rodent
SPINKs (N4, N5, N6 and N8) distributed within the down half of the phylogenetic tree.
Clade 4 comprises 3 SPINKs isoforms (SPINK1, SPINK2 and SPINK10) and expanded rat
N2.
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  C                C       C          C  C     V GTD TY N  L ELN DDFKK...GERDGDFI PDYYEA GK D R A A N
mSPINK5-d2 
      	 
	
	

  C                C       C          C  C     V GTD TY G  L ELN ESFKQ...RRKDGDFI PSDTSS GK R R E A N
rSPINK5-d2 
      	 
	
	

  C                C       C          C  C     V GTD TY S  L ELN ENFKQ...RRKDGDFI PSDASA GK P R H A N
mBAB32081  
      	 
	
	

  C                C       C          C  C     V GTD TY N  F TAF SNYEK...TLAPDGKS PKTHKP GK Q R A Q A
rN3        
      	 
	
	

  C                C       C          C  C     V GTD TY N  F TAF NNYEK...TLATDGKS PKIHKP GK Q R E Q A
hSPINK9    
      	 
	
	

  C                C       C          C  C     I GSD TY N  F KVD SHYKK...LPPGQQRF HHMYDP GK K D F S V
hSPINK8    
      	 
	
	

  C                C       C          C  C     V ASN TF N  F EPR KMYIP...LDPDYNAD PNVTAP GH Q E F V Q
mSPINK8    
      	 
	
	

  C                C       C          C  C     V ATN TY N  F DPP KMYYP...IDPDYEAN PDVKAY GL K E F I R
rSPINK8    
      	 
	
	

  C                C       C          C  C     V ATN NY N  F DPP KMYYP...IDPDYEAN PDVIAL GL K E F I R
mN7        
      	 
	
	

  C                C       C          C  C     L ASN TY N  Y AIS SHYQK...KSVQRKHT SIRVSP NV P S V F N
rN7        
      	 
	
	

  C                C       C          C  C     L ASN TY N  Y AIS SHYQK...KSVQRKHT SIRVSP NV P S V F N
hSPINK10-d1
      	 
	
	

  C                C       C          C  C     I GTD TY N  F QVN SRYIK...GL...KTA PRDWRP QK S E M M N
hSPINK7    
      	 
	
	

  C                C       C          C  C     I GTN TY N  L EVK PYEKVNLSWYNGTVNP PGLYQP FI D P I V S
mSPINK7    
      	 
	
	

  C                C       C          C  C     I GTN TY N  L EIK PYKKVNLSWFNKTVDP PDLKQP FV D P I V S
rSPINK7    
       
  C                C       C          C  C     I GTN TY N  L EIK PYKKVKLSWFNKTVDP PGLKQP FV D P I V S
Figure 4.7: Multiple alignment of the kazal domains of the SPINKs protein family. The
partner kazal domain sequences have been truncated to improve the alignment. Numbers
in parentheses refer to the kazal-like region used for alignment if the sequence contains
more than one repeat. The reserved amino acids are shaded in red.
4.3 Structural and functional implications for the novel
SFTP/SPINK gene products based on comparative sequence
analysis
The clustered organization of SFTP and SPINK genes provides a powerful opportunity to
examine gene gain and loss in evolution because physical linkage is a keydiagnostic feature
which allows homology to be established unambiguously. The availability of several com-
pleted eukaryotic genome sequences allowed us to carry out large-scale searches for novel
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Figure 4.8: Unrooted cladogram of the human SPINK family and their ortholog in mouse and rat.
The tree was subdivided into four clades.
members of previously identified protein families and to perform ”phylogenomic” analy-
ses, i.e. functional predictions via phylogenetic analysis. The premise of phylogenomics
(Eisen, 1998) is that only the analyses carried out for complete sets of proteins obtained
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from whole genomes allow to make accurate inferences of the duplication/speciation pat-
terns, identification of orthologs and paralogs, and mapping on known functions onto the
evolutionary tree (Zmasek and Eddy, 2001; 2002). Thereby, functions of uncharacterized
genes can be predicted by their phylogenetic position relative to the characterized ones,
and by analyzing the rates and patterns of gene evolution (Eisen, 1998; Eisen and Wu,
2002; Eisen and Fraser, 2003).
Based on the phylogenetic considerations supported by structure prediction and iden-
tification of characteristic conserved protein domain, all so far uncharacterized ortholog
members of the SFTP/SPINK family in chimpanzee, mouse, rat and dog were predicted.
In addition to such an ancient evolutionary origin, a multicistronic gene cluster sometimes
results from horizontal transfer between species (Lawrence and Roth, 1996; Xu et al., 1998).
Fig. 4.2 summarized comparative chromosome localization of human andmouse SFTP
genes. The human, mouse and rat (not shown) SFTP genes cluster at syntenic loci (5q32,
3F2 and 2q34, respectively). The relative positions and opposing orientations of human
hTHHL1, hTHH, hRPTN, hHRNR, hPFLG, hIFPS and hC1orf10 are matched in the mouse
locus bymTHHL1,mTHH,mRPTN,mHRNR,mPFLG,mIFPS andmC1orf10, which confirms
that human SFTPs and mouse SFTPs are orthologues. Thus the phylogenetic relationship
of the SFTP genes, reflected in Fig. 4.3, is supported by the analysis of gene structure.
Comparative genomic analysis, on the other hand, localizedorthologmatches of thehuman
EDC region (between S100A11 and S100A1) in chimpanzee, mouse, rat and dog (Fig. 4.9).
The EDC contains two highly conserved segments: segment A, between S100A11 and
SPRR2C, which contains the SFTP family; segment B, between S100A9 and S100A1. The
segment A is localized just before the segment B in human and chimpanzee, whereas the
segmentA is inverted and localized after the segment B inmouse and rat. In dog, bothwere
apparently redistributed to two different chromosomes, the segment A being localized in
chromosome 17 and the segment B being inverted and localized in chromosome 7. These
data suggest the SFTPgene cluster be an extremely conserved gene familywithinmammals
and that genomic identity and locations of the SFTP gene cluster date back as far as the
dawn of mammals. This would suggest an early process of cluster nucleation (Glusman et
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al., 2000). This was consistent with the notion that the cluster has undergone few species-
specific rearrangements or segmental duplications in the past 15 million years (Bailey et
al., 2004; Zhou and Mishra, 2005). There may be a basic function shared by all family
members that has been co-opted in mammals to become part of the CCE structure.
Fig. 4.6 summarized comparative chromosome localization of human, mouse and rat
SPINKs genes. In most genes (SPINK1, SPINK3, SPINK5, SPINK6, SPINK7, SPINK8 and
ECG2) a genomic structure of coding exons is totally conserved, including the positions
of the exon-intron boundaries. The ortholog relationship was confirmed by phylogenetic
analysis (Fig. 4.8). In contrast to the closely clustered genome structure of the human
SPINKs at chromosome region 5q32, themouse SPINKs orthologsmapped to two separate
segment regions, SPINK3 cluster to 18C and ECG2 to 18E1. Likewise, the rat SPINKs
orthologs mapped to two separate chromosome regions, SPINK1 to chromosome region
18p11 and ECG2 to chromosome region 18q12.1. However, no recognizable mouse/rat
ortholog was detected for human SPINK9 and SPINK10 in the corresponding syntenic
region, and moreover the mouse and rat SPINKs have showed expanded orthologs. One
of these (mN7 or rN7) is localized at the putative genome site ortholog to human SPINK9
but with a low homology and an inverted transcription direction. On the other hand,
mouse BAB32081 seems ortholog to hSPINK9 according to the tree. Nevertheless, the
human SPINK9 accumulated more mutations than the other family members in genome
evolution so that it possibly gains new function. This would suggest that the human
SPINK cluster displays a more complex evolutionary history.
Therefore, identification of the above two gene clusters confirms that selection can act
on entire groups of genes, leading to joint transfers of genes between genomes (Koonin et
al., 2001; Lawrence, 1997), concerted gene loss (Aravind et al., 2000), gene fusion events
(Snel et al., 2000), co-regulation of genes through common regulatory elements (Pilpel
et al., 2001), and the creation and maintenance of operons containing nonhomologous
but co-transcribed genes (Lawrence, 2002; Lathe et al., 2000). In addition, it has also
been confirmed conserved gene clusters accurately convey functional coupling between
the genes present in them (Overbeek et al., 1999). Moreover, evolutionarily selected (and
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Figure 4.9: Comparative analysis of the human epidermal differentiation complex (EDC) at 1q21
with the corresponding region of chimpanzee, mouse, rat and dog genome. The human EDC
region between S100A11 and S100A1 was used for ortholog analysis on Ensemble Genome Sever.
Orthology segment is indicated by parallel lines.
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thereby, functional) gene clustersmake apave to bephysically linked together (and thereby,
co-regulated).
It is of great interest to compare the equivalent chromosomal regions in the genomes
of different species and in particular of the mouse, for which many genetic aberrations
have been mapped and it’s much easier to perform a gene knock-out analysis. This may
provide insights into the evolution of a gene family as well as help in the identification
of candidate genes for human pathologies. Moreover, there are accumulated data sug-
gesting that human 1q21 be associated with some skin tumors (Kimchi et al., 2005) and
psoriasis (Giardina et al., 2004) while 5q32 be associated with the 5q-syndrome and atopy
(Boultwood et al., 2002; Marsh et al., 1994). The peak of linkage of AD and psoriasis on
chromosome 1q21 overlies the human epidermal differentiation complex (EDC) (Mischke
et al., 1996).
4.4 The SFTP genes expression upregulated by cross-talking of
the mitogen-activated protein kinases pathways
The conserved clusters are likely to represent functionally coupled genes, such as those
forming operon structures for co-expression and/or those encoding physically interacting
protein subunits (Tamames et al., 1997; Dandekar et al., 1998; Overbeek et al., 1999). The
proximal promoter of eachof the SFTPgenes has been analyzed inhumanandencompasses
closely situated recognitionmotifs for transcription factors suchas activatorprotein-1 (AP1)
(Jang et al., 1996), Ets (Andreoli et al., 1997), POU domain (Jang et al., 2000) and TATA box
binding protein (TBP) (Timmers et al., 1992), which are known to coordinately regulate the
activity of the promoter by binding of particularmembers of each family to their respective
sites (Jang et al., 2000) (Fig. 4.10).
In the present study, it was shown that SFTP gene members have a distinct tissue-
specific expression, though all are expressed in keratinocytes. In cultured primary ker-
atinocytes, the expression of SFTP geneswas low during the proliferative phase and highly
increased upon differentiation of the cells (Fig. 3.7). This is in agreement with all SFTPs
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genes being late differentiation markers of human keratinocytes, whose mRNA levels re-
spond to extracellular signals such as elevated calcium concentrations (Eckert and Welter,
1996). Notably, calcium-induced expression of the SFTP genes can be inhibited by either
p38 inhibitors SB202190/SB203580 or the MEK inhibitor PD98059 (Fig. 3.9). Interestingly,
the JNK inhibitor SP600125 can stimulate increased SFTPs expression at a high level though
lower than these under calcium induction (Fig. 3.8). We concluded that the silence of SFTP
promoter activity was not dependent on ERK or p38/MAP kinase but dependent on JNK.
This may indicate that the SFTP genes are under a common regulator(s) during the ker-
atinocyte differentiation. One could speculate that there are common constitutive factors
that keep the SFTP gene family locus in a transcriptionally open position but only during
a differentiating phase, and in addition to this there are tissue specific factors that apply a
specific restriction on the SFTP gene.
4.5 The SPINK7-v2: a chimeric protein encoded by two chromo-
somes
The present study characterizes a novel human gene, SPINK7-v2, that is expressed in
the bone marrow, keratinocytes and one case of precancerous lesions. Its full-length
mRNA sequence was experimentally cloned from keratinocytes. A transcription variant
of SPINK7-v2, SPINK5L2 (renamed to SPINK7-v1 here), has been recently identified in
human and mouse (Puente and Lopez-Otin, 2004). The genomic structure of both variants
explicitly demonstrates how the mRNA sequences are produced and further corroborates
the accuracy of the two mRNA sequences. As shown in Fig. 3.18, the SPINK7-v1 mRNA
sequence can be perfectly aligned with specific regions on the gene sequence, while the
SPINK7-v2 mRNA sequence can be perfectly aligned with 2 complete exons on the gene
sequence at 5q32 and a specific inverted region at chromosome 7q11.23. It is of particular
interest that, although the sequence of the SPINK7-v1 mRNA was found in the GenBank
database without a report of its detailed cloning and characterization, no sequences resem-
bling the SPINK7-v2 have been reported, nor is it predicted by computational analysis.
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Figure 4.10: Comparison of the promotor structure of the different human SFTP genes. An align-
ment of the promotor region 300-bpupstreamof the transcription start site of the eight characterized
human SFTP gene products were performed by the T-coffee program. The transcription element
effector sites important for epithelia were predicted by the TESS program and indicated by framed
lines. The dots indicating gaps were inserted for optimal sequence alignment.
Thus this is the first identification of the accurate genomic structure of this chimeric gene.
A comparison of the protein-domain structure of allmembers of the human SPINK fam-
ily, was performed to predict possible functions of the newmembers. All members display
a highly conserved kazal domain, the essential components for serine protease inhibitors.
The difference between the two isoforms of SPINK7 is the substitution of a signal-peptide
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(SP) in the amino terminus of SPINK7-v2 which may result in the secretory disturbance.
Thus it can be predicted that these two isoforms may have differential substrate specifici-
ties or other protein-protein interaction differences. It may also be that they are localized
in different cell compartments. These predictions still need to be experimentally verified.
Transposable elements (TEs)-transposons and retroposons, are a major source of ge-
netic change, including the creation of novel genes, the alteration of gene expression in
development, and the genesis of major genomic rearrangements (Lozovskaya et al., 1995).
Transposition of a TE into or near a particular host gene might impose novel developmen-
tal control on this host gene. Recent observations have shown that a number of sequences
of known mobile elements were frequently inserted into the DNA of a gene regions and
can influence the regulation of a gene’s expression (Britten, 1997). A mobile element has
also been found to be inserted in many unrelated genes in Rickettsia conorii suggesting
the potential role of selfish DNA in the creation of new protein sequences (Ogata et al.,
2000). In this study a human endogenous retrovirus sequence and an Alu sequence were
found in the SPINK7-v2 transcript. Both of the retrovirus sequence and Alu sequence have
replaced exons 1 and 2 of the gene SPINK7 and generated a SPINK7-v2 mRNA with a 5’
sequence derived from the TE. Vansant and Reynolds have observed that Alu sequences
include functional binding sites for retinoic acid (RA) receptors (Vansant and Reynolds,
1995), suggesting that the SPINK7-v2 gene containing Alu sequence in its promoter might
be involved in diverse and yet interconnected biological processes, such as embryogenesis,
growth, and differentiation (De Luca, 1991;Ross et al., 2000).
4.6 The SPINK9 product: LEKTI-2
The family of kazal-type protease inhibitors (SPINKs) inhibit serine peptidases of the S1
family, such as trypsin and elastase (Rawlings et al., 2004). During the last decade there has
been intensive investigation into the biological effects of SPINKs. To date, three members
of this family: SPINK1, ECG2 and SPINK5/LEKTI have been identified at chromosome
5q32. SPINK1 acts as the first line of defence against prematurely activated trypsinogen
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by inhibiting approximately 20% of total trypsin activity within the pancreas (Horii et
al., 1987). SPINK1 has been found to be associated with chronic pancreatitis (Chen et
al., 2000; Witt et al., 2000). ECG2 may play an important role in the carcinogenesis of
esophageal cancer (Cui et al., 2003). LEKTI is a protease inhibitor protein and is encoded
by the gene SPINK5 (Ma¨gert et al., 1999). LEKTI regulates proteolysis in epithelia forma-
tion and keratinocyte terminal differentiation, and its defects lead to overdesquamation of
corneocytes and skin barrier dysfunction (Komatsu et al., 2002). Several mutations in the
SPINK5 gene can cause Netherton syndrome, a rare autosomal recessive disorder char-
acterized by defective cornification of the skin and TH2-skewed immunologic alterations
resembling atopic dermatitis (AD) (Chavanas et al., 2000). Recently it has been revealed
that LEKTI deficiency causes abnormal desmosome cleavage in the upper granular layer
through degradation of desmoglein 1 due to stratum corneum tryptic enzyme and stratum
corneum chymotryptic enzyme-like hyperactivity (Descargues et al., 2005). This leads to
defective stratum corneum adhesion and resultant loss of skin barrier function. This work
implies that SPINKs might be key regulators of epidermal protease activity.
The present studydissects the SPINK cluster at chromosome 5q32. This result is the first
step toward comprehensive characterization of the putative genes for skin diseases. As a
good example, this study characterizes the novel gene SPINK9 and its mature protein. It is
proposed to be a secreted protein. The full-length protein of SPINK9 is autoprocessed to
form the mature protein LEKTI-2 by removing the first 25 amino acids. This autocatalytic
cleavage results in amature LEKTI-2 protein containing a complete kazal domain sequence
highly homologous with the domains 2 and 15 of LEKTI. Determination of potential P1
and P1’ sites as shown in Fig. 4.4 confirms the supposed function of the protein as a serine
proteinase inhibitor. Like LEKTI, LEKTI-2 is also highly expressed in the thymus, which
suggests the possibility of a comparable function in the regulation of the maturation of
T-lymphocytes.
As yet, the biological function of LEKTI-2 is unclear. One SPINK protein isolated from
the skin of Phyllomedusa sauvagii (PSKP-1) is described to exhibit antibacterial properties
(Gebhard et al., 2004), which suggests that SPINKsmight also involved in innate immunity.
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In this study recombinant LEKTI-2 exerts only antifungal activity (Table 3.3), whereas the
natural mature LEKTI-2 possesses E. coli-killing activity (Fig. 1.1). This difference may
result from thewrong folding of recombinant LEKTI-2 inE. coli cells. Further investigations
are now necessary to determine the target proteinase of LEKTI-2, its function within the
thymus and stratum corneum, the inhibitory potency of the Kazal-type domain, and to
clarify the pathophysiological role of LEKTI-2.
4.7 The hornerin
Hornerin, as one member of the SFTP gene family, was first found to be expressed in
mouse stratified epithelium, including the epidermis, tongue, esophagus, and forestom-
ach (Makino et al., 2001). Mouse hornerin is colocalized with profilaggrin in keratohyalin
granules in keratinocytes in the granular layer (Makino et al., 2003). Thepresent study char-
acterizes the hornerin ortholog in human by RT-PCR and phylogenetic analysis. Human
hornerin was not detected in esophagus (data not shown) but in tongue and forestomach.
Unexpectedly, humanhornerin is expressed in bonemarrowandneutrophils because other
SFTP members are not detected there.
The full-length protein of hornerin is autoprocessed to forman array of repeatedmature
peptides, one of which has been isolated from healthy skin. This autocatalytic cleavage
results in numerous peaks in ESI-MS RP-HPLC analysis of natural hornerin-containing
stratum corneum extracts from skin (data not shown). This process was also confirmed by
recombinant protein analysis shown in Fig. 3.28, suggesting that human hornerin contain
trypsin-like protease activity. The recombinant polypeptides display antimicrobial activity
to Gram-negative bacteria and fungi, especially the HRNR3 whose amino acid sequence
was deduced from the natural mature peptide. HRNR3 showed much higher activity
than the other recombinant hornerin fragments in this study (Table 3.3). Detection of
microbial activity of hornerin was very surprising, because hornerin is generally viewed
as a structural proprotein involved in formation of CCE (Makino et al., 2001). Thus, these
data indicate that human hornerin appears to be proteolytically processed in vivo to give
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rise to antibiotic activity against several microorganisms.
4.8 The polyclonal goat antisera against hornerin fragments and
LEKTI-2
Recombinant LEKTI-2 and hornerin-fragments were used to immunize goats. The high ac-
tivity of the resulting goat antisera against hornerin fragments and LEKTI-2was confirmed
by dot-blot assays using recombinant as well as natural antigens purified by reversed-
phase-HPLC. These experiments demonstrated that it is possible to generate polyclonal
antibodies against hornerin fragments and LEKTI-2. These new generated antibodies
have been found to be an useful tool to detect LEKTI-2 and hornerin fragments in HPLC-
fractions of human skin extracts (data not shown). Further investigations are necessary to
verify the specificity of the generated antisera (e.g. by using western-blot analysis). Spe-
cific antibodies against hornerin fragments and LEKTI-2 would help to investigate protein
expression and to determine whether gene expression correlates with protein expression.
If the antibodies might work in immunohistochemistry, analysis of the cellular expression
pattern of hornerin fragments and LEKTI-2 in various tissues would be possible.
Abstract
Human body surfaces are defended by epithelia, which provide the initial physical barrier
against potential harmful microorganisms. Epithelia also provide chemical barriers to
microbial colonization including low pH, hydrolytic enzymes, and defensemolecules such
as antimicrobial peptides (AMPs). The number of reports demonstrating the presence
and upregulation of AMPs in human skin is increasing and reflects the significance of
these peptides in cutaneous innate immunity. This thesis has performed an exhaustive
characterization of two coherent gene clusters, S100 fused-type proteins (SFTP) and kazal-
type serine protease inhibitors (SPINK), with a part of the effort to elucidate the molecular
mechanism of innate immunity in the skin. Included is expression analyses of various
novel genes identified in primary keratinocytes and generation of goat antisera against
recombinant hornerin fragments and recombinant LEKTI-2, respectively.
SFTPproteins comprise a conserved familyof intermediatefilament-associatedproteins
involved in keratinocyte terminal differentiation. Three human SFTP genes have been
identified so far. Here the identification of four additional SFTPmembers (THHL1, Repetin,
Hornerin and Ifapsoriasin) is reported. All the seven genes were identified as a cluster
localized within the epidermal differentiation complex (EDC) on chromosome 1q21.3, a
region of shared synteny with mouse chromosome 3F2 and rat chromosome 2q34. Several
points of evidence, including a strong similarity in protein structure, a conserved linear
gene order and the positions of the exon-intron boundaries, suggest that the SFTP clusters
in human, mouse and rat are orthologous and share a common conserved function. The
maintenance of one cognate SFTP gene cluster during vertebrate evolution suggests that
their genomic organization should be important for the regulation, expression and function
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of SFTP genes.
Serine protease inhibitors kazal type (SPINKs) are a group of small secreted proteins,
which play an important role in the pathology of diseases such as arthritis, cancer, multiple
sclerosis and cardiovascular diseases. To obtain fundamental information about the human
SPINK gene cluster, the genomic structure of 5q32 was analyzed. Five novel members
of SPINK genes were identified by in-silico analysis and RT-PCR and characterized by
sequence homology, conserved kazal domain, a clustered localization and gene expression
on keratinocytes. In contrast to the conserved SFTP genes, the SPINK genes showed
extensive species differences, including expansions of gene subsets, gene deletions, exon
shuﬄing generating a hybrid gene (SPINK7) and accelerated accumulation of mutations
in the kazal domain.
To better understand the biology and function of both gene clusters, patterns of
SFTP/SPINK gene expression in human foreskin derived primary keratinocytes, human
adult tissues, human skin tumors and other diseaseswere studied. Both gene clusterswere
expressed in keratinocytes but in a different range of tissue types. Genes of the SFTP clus-
ter were found to have distinct patterns that correlated with variation in diseased lesions.
Their mRNA expression was activated upon calcium stimulation resulting in keratinocyte
differentiation, and were found to be under upstream positive induction of the ERK/p38
MAPK signal transduction pathway and under negative upstream induction of the JNK
pathway, respectively.
Using recombinant expression of hornerin fragments as fusion proteins, surprisingly
it was found that the hornerin proprotein was processed by an unknown mechanism
(possible self digestion) into multiple novel antimicrobial peptides. This indicated that
hornerin not only might function as an intermediate filament-associated structural protein
but also might play multiple roles in the regulation of human skin flora as a precursor
molecule of antimicrobial peptides. These peptides may help limit infection by potential
pathogens in the first few hours following bacterial colonization.
Further generation of recombinant SPINK9 gene product, LEKTI-2, revealed so far only
low antimicrobial activity. It is suggested that the native peptide could be modified by
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posttranslational actions, which may enhance antimicrobial activity.
The SPINK7 gene product appears to be a putative chimeric fusion protein encoded
by two chromosomes and is expressed in bone marrow, skin tumor (precancerous lesions)
and in cultured keratinocytes. Though the function remains to be characterized, SPINK7
will be a useful model to investigate the molecular mechanism leading to the expression
of one gene derived from different chromosomes.
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Die Körperoberflächen des Menschen werden durch die Epithelien geschützt, welche 
eine erste physikalische Barriere gegen potentiell schädliche Mikroorganismen 
darstellen. Die Epithelien bieten als weiteren Schutz vor mikrobieller Besiedlung auch 
eine chemische Barriere, welche durch einen niedrigen pH-Wert, hydrolytische Enzyme 
und Abwehrmoleküle, wie zum Beispiel antimikrobielle Peptide (AMPs), 
gekennzeichnet ist. Die zunehmende Anzahl an Veröffentlichungen über das 
Vorkommen und die Induktion von AMPs in der Haut des Menschen spiegelt die 
Bedeutung von diesen Peptiden für die angeborene Abwehr („innate immunity“) der 
Haut wieder. In dieser Arbeit wurde eine eingehende Untersuchung der zwei 
zusammenhängenden Gen-Cluster von „S100-fused type proteins“ (SFTP) und Serin 
Protease-Inhibitoren vom Kazal-Typ („kazal-type serine protease inhibitors, SPINK) 
durchgeführt, um weitere Einblicke in die molekularen Mechanismen der angeborenen 
Abwehr der Haut zu erhalten. Untersuchungen zur Expression verschiedener in primären 
Keratinozyten neu identifizierter Gene wurden durchgeführt und Ziegen-Antiseren 
gegen rekombinante Hornerin-Fragmente und rekombinantes LEKTI-2 hergestellt. 
SFTP Proteine gehören zur konservierten Familie der „intermediate filament-associated 
proteins“, einer Gruppe von Proteinen, die in die terminale Differenzierung der 
Keratinozyten involviert sind. Bis jetzt wurden drei humane SFTP-Gene identifiziert. In 
dieser Arbeit wird die Identifikation von vier weiteren SFTP-Mitgliedern (THHL1, 
Repetin, Hornerin und Ifapsoriasin) beschrieben. Alle sieben SFTP-Gene liegen 
zusammen auf einem Gen-Cluster des epidermalen Differenzierungs-Komplexes 
(„epidermal differentiation complex“, EDC) auf Chromosom 1q21.3, einem 
chromosomalen Abschnitt mit Ähnlichkeit zu Maus-Chromosom 3F2 und Chromosom 
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2q34 der Ratte. Eine hohe Ähnlichkeit der Protein-Struktur, eine konservierte lineare 
Gen-Anordnung und die Exon-Intron-Abfolge legen nahe, dass die SFTP-Cluster im 
Menschen, Maus und Ratte ortholog sind und eine gemeinsame konservierte Funktion 
aufweisen. Die Erhaltung eines verwandten SFTP-Gen-Clusters während der Evolution 
der Vertebraten legt die Vermutung nahe, dass die genomische Organisation der SFTP-
Gene im SFTP-Cluster für deren Expression, Regulation und Funktion von wichtiger 
Bedeutung sein könnte. 
Serin Protease-Inhibitoren vom Kazal-Typ (SPINKs) sind eine Gruppe von kleinen 
sezernierten Proteinen, welche eine wichtige Bedeutung für die Pathologie von Arthritis, 
Krebs, Multipler Sklerose und kardiovaskulären Erkrankungen besitzen. Um detaillierte 
Informationen über das  SPINK-Gen-Cluster zu erhalten, wurde die genomische Struktur 
von 5q32 analysiert. Fünf neue Mitglieder der SPINK-Gen Familie konnten durch in-
silico- Analyse und RT-PCR identifiziert werden. Diese Gene zeichnen sich durch eine 
hohe Sequenz-Homologie, durch eine konservierte Kazal-Domäne, durch eine 
geclusterte Lokalisation und durch eine Expression in Keratinozyten aus. Im Gegensatz 
zu den konservierten SFTP-Genen besitzen die SPINK-Gene große Spezies-abhängige 
Unterschiede einschließlich einer Expansion bestimmter Genabschnitte, Gen-
Deletionen, Exon-Verschiebungen und Entstehung eines Hybrid-Gens (SPINK7) und 
einer erhöhten Häufigkeit von Mutationen in der Kazal-Domäne. 
Um die funktionelle und biologische Rolle des SFTP- und SPINK-Gen-Clusters näher 
zu charakterisieren, wurde die Expression der SFTP- und SPINK-Gene in humanen 
Vorhaut-Keratinozyten und adulten Geweben einschließlich erkrankten Geweben, wie 
zum Beispiel Haut-Tumoren, analysiert. Es zeigte sich, dass beide Gen-Cluster in 
Keratinozyten exprimiert werden, aber in anderen Geweben ein unterschiedliches 
Expressionsprofil aufweisen. Insbesondere die Expression der Gene des SFTP-Clusters 
korrelierte mit der Ausprägung von erkrankten Läsionen. Die mRNA-Expression der 
SFTP-Gene wurde im Zuge der durch erhöhte Kalzium-Konzentrationen ausgelösten 
Keratinozyten-Differenzierung aktiviert und  durch den ERK/p38 MAP-Kinase-
Signalweg positiv reguliert und durch den JNK-Signalweg negativ reguliert. 
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Die Expression von rekombinanten Hornerin-Fragmenten ergab, dass das Hornerin-
Proprotein überraschenderweise durch noch unbekannte Mechanismen (möglicherweise 
durch autokatalytischen Verdau) in mehrere neue antimikrobielle Peptide prozessiert 
wird. Dies zeigt, dass  Hornerin möglicherweise nicht nur als Struktur-Protein (als ein 
„intermediate filament-associated Protein“) fungiert, sondern auch eine Bedeutung für 
die Regulation der menschlichen Hautflora durch die Bereitstellung antimikrobieller 
Peptide haben könnte. Solche antimikrobiellen Peptide könnten dazu beitragen, schon in 
den ersten Stunden nach bakterieller Besiedlung die Entstehung von Infektionen zu 
verhindern. 
Die Verwendung von rekombinantem Material des SPINK9-Genprodukts LEKTI-2 
ergab bisher nur eine niedrige antimikrobielle Aktivität. Es wäre möglich, dass das 
native Peptid aufgrund von postranslationalen Modifikationen eine gesteigerte 
antimikrobielle Aktivität aufweist.  
Das SPINK7 Genprodukt stellt ein putatives chimäres Fusionsprotein dar, dessen 
Information auf zwei Chromosomen kodiert ist. SPINK7 wird im Knochenmark, Haut-
Tumoren (präkanzerösen Läsionen) und in kultivierten Keratinozyten exprimiert. 
Obwohl die Funktion von SPINK7 noch charakterisiert werden muß, so könnte es doch 
ein nützliches Modell darstellen, um die molekularen Mechanismen zu analysieren, die 
zur Expression eines von zwei verschiedenen Chromosomen abstammenden Gens 
führen. 
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Appendix 
 
5.1 Nucleotide and amino acid sequences of human THHL1 cDNA. The full-length 
nucleotide sequence of human THHL1 cDNA (3603 bp) was verified by direct cDNA cloning 
and sequencing and aligned with the predicted open reading frame amino acid sequence. The 
underlined red nucleotides indicate the canonical poly(A) addition signal. The exon/intron 
boundaries were determined by the BLAT Search. Sequence data have been deposited under 
the GenBankTM accession no. AY456639. 
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5.2 Nucleotide and amino acid sequences of human repetin cDNA. The full-length 
nucleotide sequence of human hornerin cDNA (3569 bp) was verified by direct cDNA 
cloning and sequencing and aligned with the predicted open reading frame amino acid 
sequence. The underlined red nucleotides indicate the canonical poly(A) addition signal. The 
exon/intron boundaries were determined by the BLAT Search. Sequence data have been 
deposited under the GenBankTM accession no. AY396742. 
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5.3 Nucleotide and amino acid sequences of human hornerin cDNA. The full-le
nucleotide sequence of human hornerin cDNA (9632 bp) was verified by direct cD
cloning and sequencing and aligned with the predicted open reading frame amino 
sequence. The underlined red nucleotides indicate the canonical poly(A) addition signal. 
exon/intron boundaries were determined by the BLAT Search. Sequence data have b
deposited under the GenBankTM accession no. AY396741. 
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5.4  Nucleotide and amino acid sequences of human ifapsoriasin cDNA. The full-le
nucleotide sequence of human ifapsoriasin cDNA (9117 bp) was verified by direct cD
cloning and sequencing and aligned with the predicted open reading frame amino acid seque
The underlined red nucleotides indicate the canonical poly(A) addition signal. The exon/in
boundaries were determined by the BLAT Search. Sequence data have been deposited under
GenBankTM accession no. AY827490.      11ngth 
NA 
nce. 
tron 
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